Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:bile acid conjugate
go back to main search page
Accession:CHEBI:36249 term browser browse the term
Definition:A glycine or taurine amide of a bile acid.
Synonyms:related_synonym: bile acid conjugates


show annotations for term's descendants           Sort by:
 
glycochenodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA CTD PMID:32152650 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G ABCC4 ATP binding cassette subfamily C member 4 multiple interactions EXP [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
JBrowse link
G AGT angiotensinogen multiple interactions
decreases response to substance
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA]; AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; AGTR1 protein promotes the reaction [AGT protein results in decreased susceptibility to Glycochenodeoxycholic Acid]; candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; irbesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Losartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; U 0126 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Valsartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]] CTD PMID:23300732 NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,702,523...230,714,122
JBrowse link
G AGTR1 angiotensin II receptor type 1 multiple interactions ISO AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; AGTR1 protein promotes the reaction [AGT protein results in decreased susceptibility to Glycochenodeoxycholic Acid] CTD PMID:23300732 NCBI chr 3:148,697,871...148,743,003
Ensembl chr 3:148,697,784...148,743,008
JBrowse link
G AKR1A1 aldo-keto reductase family 1 member A1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 1:45,550,779...45,570,051
Ensembl chr 1:45,550,543...45,570,049
JBrowse link
G AKR7A2 aldo-keto reductase family 7 member A2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,303,965...19,312,146
JBrowse link
G AKR7A3 aldo-keto reductase family 7 member A3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 NCBI chr 1:19,274,229...19,289,362
Ensembl chr 1:19,282,573...19,288,770
JBrowse link
G AOX1 aldehyde oxidase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 2:200,585,952...200,677,064
Ensembl chr 2:200,586,014...200,677,064
JBrowse link
G ATF4 activating transcription factor 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr22:39,514,494...39,522,686
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
JBrowse link
G ATF6 activating transcription factor 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,320...161,964,070
JBrowse link
G ATG5 autophagy related 5 decreases expression
multiple interactions
EXP Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA; Glycochenodeoxycholic Acid results in decreased expression of ATG5 protein
TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA]
CTD PMID:32439580 NCBI chr 6:106,184,476...106,325,789
Ensembl chr 6:106,045,423...106,325,791
JBrowse link
G ATG7 autophagy related 7 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 3:11,272,348...11,564,652
Ensembl chr 3:11,272,309...11,557,665
JBrowse link
G ATP6V0D1 ATPase H+ transporting V0 subunit d1 decreases expression EXP Glycochenodeoxycholic Acid results in decreased expression of ATP6V0D1 mRNA CTD PMID:32439580 NCBI chr16:67,438,019...67,481,157
Ensembl chr16:67,438,014...67,481,181
JBrowse link
G ATP6V1E1 ATPase H+ transporting V1 subunit E1 decreases expression EXP Glycochenodeoxycholic Acid results in decreased expression of ATP6V1E1 mRNA CTD PMID:32439580 NCBI chr22:17,592,136...17,628,822
Ensembl chr22:17,592,136...17,628,749
JBrowse link
G BCL2A1 BCL2 related protein A1 increases expression ISO Glycochenodeoxycholic Acid results in increased expression of BCL2A1 mRNA CTD PMID:15767249 NCBI chr15:79,960,892...79,971,196
Ensembl chr15:79,960,892...79,971,196
JBrowse link
G BCL2L13 BCL2 like 13 decreases expression EXP Glycochenodeoxycholic Acid results in decreased expression of BCL2L13 protein CTD PMID:32439580 NCBI chr22:17,628,855...17,730,855
Ensembl chr22:17,628,855...17,730,855
JBrowse link
G BECN1 beclin 1 multiple interactions
decreases expression
EXP TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA]
Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA; Glycochenodeoxycholic Acid results in decreased expression of BECN1 protein
CTD PMID:32439580 NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
JBrowse link
G BIRC5 baculoviral IAP repeat containing 5 increases expression ISO Glycochenodeoxycholic Acid results in increased expression of BIRC5 mRNA CTD PMID:15767249 NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
JBrowse link
G CASP3 caspase 3 multiple interactions
increases cleavage
increases activity
EXP
ISO
Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Calcimycin inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Egtazic Acid promotes the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Nitric Oxide inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Sulfasalazine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in increased cleavage of CASP3 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; irbesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Losartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; U 0126 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Valsartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]
CTD PMID:12873810, PMID:15767249, PMID:16322111, PMID:19837105, PMID:20020783, PMID:23300732, PMID:25125499 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CASP8 caspase 8 increases activity
increases cleavage
ISO Glycochenodeoxycholic Acid results in increased activity of CASP8 protein
Glycochenodeoxycholic Acid results in increased cleavage of CASP8 protein
CTD PMID:12873810, PMID:15767249, PMID:25125499 NCBI chr 2:201,233,443...201,287,711
Ensembl chr 2:201,233,443...201,287,711
JBrowse link
G CASP9 caspase 9 increases activity
multiple interactions
ISO
EXP
Glycochenodeoxycholic Acid results in increased activity of CASP9 protein
Sulfasalazine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP9 protein]
CTD PMID:15767249, PMID:16322111 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
JBrowse link
G CAT catalase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
JBrowse link
G CBR1 carbonyl reductase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166
JBrowse link
G CCR2 C-C motif chemokine receptor 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 3:46,354,111...46,360,940
Ensembl chr 3:46,353,744...46,360,940
Ensembl chr 3:46,353,744...46,360,940
JBrowse link
G CFLAR CASP8 and FADD like apoptosis regulator multiple interactions
increases expression
EXP
ISO
Glycochenodeoxycholic Acid results in decreased expression of and results in increased phosphorylation of CFLAR protein
Glycochenodeoxycholic Acid results in increased expression of CFLAR protein
Glycochenodeoxycholic Acid promotes the reaction [lysophosphatidylethanolamine analog results in increased expression of CFLAR protein]; lysophosphatidylethanolamine analog promotes the reaction [Glycochenodeoxycholic Acid results in increased expression of CFLAR protein]
CTD PMID:25125499 NCBI chr 2:201,116,164...201,176,687
Ensembl chr 2:201,116,154...201,176,687
JBrowse link
G CSF1 colony stimulating factor 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
JBrowse link
G CYCS cytochrome c, somatic affects localization ISO Glycochenodeoxycholic Acid affects the localization of CYCS protein CTD PMID:15767249 NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
JBrowse link
G CYLD CYLD lysine 63 deubiquitinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr16:50,742,086...50,801,935
Ensembl chr16:50,742,050...50,801,935
JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA CTD PMID:32152650 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
JBrowse link
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions
increases expression
ISO
EXP
AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA
CTD PMID:23300732, PMID:32152650 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DNAJB1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:14,514,769...14,530,597
Ensembl chr19:14,514,769...14,529,770
JBrowse link
G DNAJB11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr 3:186,570,720...186,585,793
Ensembl chr 3:186,567,403...186,585,800
JBrowse link
G DNAJB6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 7:157,337,004...157,417,439
Ensembl chr 7:157,335,381...157,417,439
JBrowse link
G DNAJB9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850
JBrowse link
G DNAJC1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr10:21,756,548...22,003,763
Ensembl chr10:21,756,548...22,003,769
JBrowse link
G DNAJC10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 2:182,716,257...182,794,464
Ensembl chr 2:182,716,041...182,794,464
JBrowse link
G DNAJC16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 1:15,526,694...15,571,987
Ensembl chr 1:15,526,813...15,592,379
JBrowse link
G DNAJC18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr 5:139,410,203...139,439,525
Ensembl chr 5:139,408,588...139,444,491
JBrowse link
G DNAJC19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 3:180,983,709...180,989,838
Ensembl chr 3:180,983,709...180,989,774
JBrowse link
G DNAJC21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 5:34,929,540...34,958,964
Ensembl chr 5:34,929,559...34,958,964
JBrowse link
G DNAJC3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr13:95,677,139...95,794,988
Ensembl chr13:95,677,139...95,794,988
JBrowse link
G DNAJC6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 1:65,264,749...65,415,871
Ensembl chr 1:65,248,219...65,415,871
JBrowse link
G DNAJC9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr10:73,241,954...73,247,255
Ensembl chr10:73,183,362...73,247,255
Ensembl chr10:73,183,362...73,247,255
JBrowse link
G ENC1 ectodermal-neural cortex 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 5:74,627,409...74,640,728
Ensembl chr 5:74,627,406...74,641,424
JBrowse link
G EPHX1 epoxide hydrolase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,092...225,845,563
JBrowse link
G FKBP5 FKBP prolyl isomerase 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583
JBrowse link
G FMO1 flavin containing dimethylaniline monoxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr 1:171,248,473...171,285,978
Ensembl chr 1:171,248,471...171,285,978
JBrowse link
G FOSL1 FOS like 1, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
JBrowse link
G GPX2 glutathione peroxidase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,905
JBrowse link
G GSTA1 glutathione S-transferase alpha 1 multiple interactions ISO
EXP
Glycochenodeoxycholic Acid binds to [GSTA1 protein co-treated with GSTA1 protein]; Glycochenodeoxycholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA
CTD PMID:3783048, PMID:32152650 NCBI chr 6:52,791,371...52,803,827
Ensembl chr 6:52,791,371...52,803,860
JBrowse link
G GSTA3 glutathione S-transferase alpha 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA CTD PMID:32152650 NCBI chr 6:52,896,646...52,909,799
Ensembl chr 6:52,896,639...52,909,698
JBrowse link
G GSTK1 glutathione S-transferase kappa 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 7:143,263,441...143,269,115
Ensembl chr 7:143,244,093...143,270,854
JBrowse link
G GSTM1 glutathione S-transferase mu 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039
JBrowse link
G GSTM2 glutathione S-transferase mu 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551
JBrowse link
G GSTM4 glutathione S-transferase mu 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 1:109,656,076...109,665,497
Ensembl chr 1:109,656,099...109,674,836
JBrowse link
G HERPUD1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr16:56,932,142...56,944,864
Ensembl chr16:56,932,142...56,944,864
JBrowse link
G HGF hepatocyte growth factor multiple interactions EXP Glycochenodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] CTD PMID:15802798 NCBI chr 7:81,699,006...81,770,438
Ensembl chr 7:81,699,010...81,770,438
JBrowse link
G HMOX1 heme oxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,207
JBrowse link
G HSD11B1 hydroxysteroid 11-beta dehydrogenase 1 decreases abundance ISO HSD11B1 gene mutant form results in decreased abundance of Glycochenodeoxycholic Acid CTD PMID:25061560 NCBI chr 1:209,686,179...209,734,929
Ensembl chr 1:209,686,178...209,734,949
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
JBrowse link
G HSPB8 heat shock protein family B (small) member 8 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
JBrowse link
G HUWE1 HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1 multiple interactions EXP Glycochenodeoxycholic Acid inhibits the reaction [HUWE1 protein binds to MCL1 protein] CTD PMID:21507240 NCBI chr  X:53,532,096...53,686,723
Ensembl chr  X:53,532,096...53,686,728
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
JBrowse link
G JUND JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr19:18,279,694...18,281,622
Ensembl chr19:18,279,694...18,281,622
JBrowse link
G MAF MAF bZIP transcription factor multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr16:79,202,624...79,601,952
Ensembl chr16:79,585,843...79,600,737
JBrowse link
G MAFF MAF bZIP transcription factor F multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507
JBrowse link
G MAFG MAF bZIP transcription factor G multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr17:81,918,270...81,927,735
Ensembl chr17:81,918,270...81,927,735
JBrowse link
G MAFK MAF bZIP transcription factor K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr 7:1,530,702...1,543,043
Ensembl chr 7:1,530,702...1,543,043
JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta multiple interactions
decreases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of MAP1LC3B mRNA] CTD PMID:32152650, PMID:32439580 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
JBrowse link
G MAP2K1 mitogen-activated protein kinase kinase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,817...66,492,312
Ensembl chr15:66,386,817...66,492,312
JBrowse link
G MAP2K2 mitogen-activated protein kinase kinase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr19:4,090,321...4,124,184
Ensembl chr19:4,090,321...4,124,129
Ensembl chr19:4,090,321...4,124,129
JBrowse link
G MAP2K6 mitogen-activated protein kinase kinase 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 increases activity
multiple interactions
EXP
ISO
Glycochenodeoxycholic Acid results in increased activity of MAPK1 protein
[AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of MAPK1 protein]
CTD PMID:21507240, PMID:23300732 NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,754,500...21,867,680
Ensembl chr22:21,754,500...21,867,680
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 increases activity
multiple interactions
EXP
ISO
Glycochenodeoxycholic Acid results in increased activity of MAPK3 protein
[AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of MAPK3 protein]
CTD PMID:21507240, PMID:23300732 NCBI chr16:30,114,105...30,123,309
Ensembl chr16:30,114,105...30,123,506
JBrowse link
G MAPK9 mitogen-activated protein kinase 9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
JBrowse link
G MAPKAPK3 MAPK activated protein kinase 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 3:50,611,877...50,649,291
Ensembl chr 3:50,611,520...50,649,291
JBrowse link
G MCL1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
increases phosphorylation
EXP
ISO
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MCL1 protein]; [Glycochenodeoxycholic Acid results in increased phosphorylation of MCL1 protein] which results in decreased degradation of MCL1 protein; Glycochenodeoxycholic Acid inhibits the reaction [HUWE1 protein binds to MCL1 protein]
Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein; lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein]
CTD PMID:21507240, PMID:25125499 NCBI chr 1:150,574,558...150,579,610
Ensembl chr 1:150,574,551...150,579,738
JBrowse link
G MGST2 microsomal glutathione S-transferase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 4:139,665,725...139,754,608
Ensembl chr 4:139,665,768...139,740,745
JBrowse link
G MLKL mixed lineage kinase domain like pseudokinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr16:74,671,855...74,700,889
Ensembl chr16:74,671,855...74,700,960
JBrowse link
G NOS2 nitric oxide synthase 2 increases expression ISO Glycochenodeoxycholic Acid results in increased expression of NOS2 mRNA CTD PMID:15767249 NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
JBrowse link
G NOS3 nitric oxide synthase 3 decreases expression
multiple interactions
EXP Glycochenodeoxycholic Acid results in decreased expression of NOS3; Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA; Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein
[Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein] which results in decreased abundance of Nitric Oxide; Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein]; Calcimycin inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3]
CTD PMID:19837105, PMID:20020783 NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
JBrowse link
G NQO2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr 6:2,999,816...3,019,876
Ensembl chr 6:2,987,987...3,021,850
Ensembl chr 6:2,987,987...3,021,850
JBrowse link
G NR1H4 nuclear receptor subfamily 1 group H member 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA CTD PMID:32152650 NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA CTD PMID:32152650 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,485
JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA CTD PMID:32152650 NCBI chr 1:161,229,666...161,238,623
Ensembl chr 1:161,229,666...161,238,302
Ensembl chr 1:161,229,666...161,238,302
JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 increases cleavage ISO Glycochenodeoxycholic Acid results in increased cleavage of PARP1 protein CTD PMID:25125499 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093
JBrowse link
G PIK3C2B phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr 1:204,422,633...204,494,815
Ensembl chr 1:204,422,628...204,494,724
JBrowse link
G PIK3C2G phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 NCBI chr12:18,242,946...18,716,861
Ensembl chr12:18,242,961...18,648,416
Ensembl chr12:18,242,961...18,648,416
JBrowse link
G PIK3C3 phosphatidylinositol 3-kinase catalytic subunit type 3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:41,955,226...42,087,830
Ensembl chr18:41,955,234...42,087,830
JBrowse link
G PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 5:68,215,737...68,301,821
Ensembl chr 5:68,215,756...68,301,821
JBrowse link
G RALA RAS like proto-oncogene A multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr 7:39,622,955...39,708,124
Ensembl chr 7:39,623,565...39,708,120
JBrowse link
G RAP1A RAP1A, member of RAS oncogene family multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 1:111,542,009...111,716,695
Ensembl chr 1:111,542,218...111,716,691
JBrowse link
G RIPK1 receptor interacting serine/threonine kinase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,991...3,115,187
JBrowse link
G RRAS2 RAS related 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr11:14,277,920...14,364,506
Ensembl chr11:14,277,922...14,364,506
JBrowse link
G SCARB1 scavenger receptor class B member 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA CTD PMID:32152650 NCBI chr12:124,776,856...124,863,864
Ensembl chr12:124,776,856...124,882,668
JBrowse link
G SERPINE1 serpin family E member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA CTD PMID:32152650 NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
JBrowse link
G SH3GLB1 SH3 domain containing GRB2 like, endophilin B1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 1:86,704,570...86,748,184
Ensembl chr 1:86,704,570...86,748,184
JBrowse link
G SLC10A1 solute carrier family 10 member 1 increases uptake
multiple interactions
EXP SLC10A1 protein results in increased uptake of Glycochenodeoxycholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA
CTD PMID:29024779, PMID:32152650 NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
JBrowse link
G SLC51A solute carrier family 51 subunit alpha multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid] CTD PMID:32152650, PMID:32294204 NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178
JBrowse link
G SLC51B solute carrier family 51 subunit beta multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid] CTD PMID:32152650, PMID:32294204 NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397
JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 increases transport
multiple interactions
EXP SLCO1B1 protein results in increased transport of Glycochenodeoxycholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA
CTD PMID:29933103, PMID:32152650 NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA CTD PMID:32152650 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
JBrowse link
G SQSTM1 sequestosome 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
JBrowse link
G STIP1 stress induced phosphoprotein 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr11:64,185,272...64,204,543
Ensembl chr11:64,185,272...64,204,543
JBrowse link
G SULT2A1 sulfotransferase family 2A member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 NCBI chr19:47,870,467...47,886,315
Ensembl chr19:47,870,467...47,886,315
JBrowse link
G TFE3 transcription factor binding to IGHM enhancer 3 multiple interactions
decreases expression
EXP Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of TFE3 mRNA]; Glycochenodeoxycholic Acid results in decreased expression of and results in decreased activity of TFE3 protein; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA]; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA]; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of MAP1LC3B mRNA] CTD PMID:32439580 NCBI chr  X:49,028,726...49,043,357
Ensembl chr  X:49,028,726...49,043,410
JBrowse link
G UBE2K ubiquitin conjugating enzyme E2 K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr 4:39,698,136...39,782,792
Ensembl chr 4:39,698,109...39,782,792
JBrowse link
G UGT2B4 UDP glucuronosyltransferase family 2 member B4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA CTD PMID:32152650 NCBI chr 4:69,480,165...69,526,014
Ensembl chr 4:69,480,165...69,526,014
JBrowse link
G USP14 ubiquitin specific peptidase 14 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:158,557...214,629
Ensembl chr18:158,383...214,629
JBrowse link
G VCP valosin containing protein multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 9:35,056,064...35,072,625
Ensembl chr 9:35,056,064...35,072,627
JBrowse link
glycocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 affects transport
multiple interactions
EXP ABCB11 protein affects the transport of Glycocholic Acid
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA
CTD PMID:15791618, PMID:32152650 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCC1 ATP binding cassette subfamily C member 1 multiple interactions EXP Glycocholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr16:15,949,616...16,143,062
Ensembl chr16:15,949,577...16,143,074
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G ABCC4 ATP binding cassette subfamily C member 4 multiple interactions EXP [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
JBrowse link
G AKR1A1 aldo-keto reductase family 1 member A1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 1:45,550,779...45,570,051
Ensembl chr 1:45,550,543...45,570,049
JBrowse link
G AKR7A2 aldo-keto reductase family 7 member A2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,303,965...19,312,146
JBrowse link
G AKR7A3 aldo-keto reductase family 7 member A3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 NCBI chr 1:19,274,229...19,289,362
Ensembl chr 1:19,282,573...19,288,770
JBrowse link
G AOX1 aldehyde oxidase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 2:200,585,952...200,677,064
Ensembl chr 2:200,586,014...200,677,064
JBrowse link
G ATF4 activating transcription factor 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr22:39,514,494...39,522,686
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
JBrowse link
G ATF6 activating transcription factor 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,320...161,964,070
JBrowse link
G ATG7 autophagy related 7 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 3:11,272,348...11,564,652
Ensembl chr 3:11,272,309...11,557,665
JBrowse link
G CAT catalase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
JBrowse link
G CBR1 carbonyl reductase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166
JBrowse link
G CCR2 C-C motif chemokine receptor 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 3:46,354,111...46,360,940
Ensembl chr 3:46,353,744...46,360,940
Ensembl chr 3:46,353,744...46,360,940
JBrowse link
G CSF1 colony stimulating factor 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
JBrowse link
G CYLD CYLD lysine 63 deubiquitinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr16:50,742,086...50,801,935
Ensembl chr16:50,742,050...50,801,935
JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA CTD PMID:32152650 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
JBrowse link
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DNAJB1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:14,514,769...14,530,597
Ensembl chr19:14,514,769...14,529,770
JBrowse link
G DNAJB11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr 3:186,570,720...186,585,793
Ensembl chr 3:186,567,403...186,585,800
JBrowse link
G DNAJB6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 7:157,337,004...157,417,439
Ensembl chr 7:157,335,381...157,417,439
JBrowse link
G DNAJB9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850
JBrowse link
G DNAJC1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr10:21,756,548...22,003,763
Ensembl chr10:21,756,548...22,003,769
JBrowse link
G DNAJC10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 2:182,716,257...182,794,464
Ensembl chr 2:182,716,041...182,794,464
JBrowse link
G DNAJC16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 1:15,526,694...15,571,987
Ensembl chr 1:15,526,813...15,592,379
JBrowse link
G DNAJC18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr 5:139,410,203...139,439,525
Ensembl chr 5:139,408,588...139,444,491
JBrowse link
G DNAJC19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 3:180,983,709...180,989,838
Ensembl chr 3:180,983,709...180,989,774
JBrowse link
G DNAJC21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 5:34,929,540...34,958,964
Ensembl chr 5:34,929,559...34,958,964
JBrowse link
G DNAJC3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr13:95,677,139...95,794,988
Ensembl chr13:95,677,139...95,794,988
JBrowse link
G DNAJC6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 1:65,264,749...65,415,871
Ensembl chr 1:65,248,219...65,415,871
JBrowse link
G DNAJC9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr10:73,241,954...73,247,255
Ensembl chr10:73,183,362...73,247,255
Ensembl chr10:73,183,362...73,247,255
JBrowse link
G ENC1 ectodermal-neural cortex 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 5:74,627,409...74,640,728
Ensembl chr 5:74,627,406...74,641,424
JBrowse link
G EPHX1 epoxide hydrolase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,092...225,845,563
JBrowse link
G FKBP5 FKBP prolyl isomerase 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583
JBrowse link
G FMO1 flavin containing dimethylaniline monoxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr 1:171,248,473...171,285,978
Ensembl chr 1:171,248,471...171,285,978
JBrowse link
G FOSL1 FOS like 1, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
JBrowse link
G GPX2 glutathione peroxidase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,905
JBrowse link
G GSTA1 glutathione S-transferase alpha 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA CTD PMID:32152650 NCBI chr 6:52,791,371...52,803,827
Ensembl chr 6:52,791,371...52,803,860
JBrowse link
G GSTA3 glutathione S-transferase alpha 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA CTD PMID:32152650 NCBI chr 6:52,896,646...52,909,799
Ensembl chr 6:52,896,639...52,909,698
JBrowse link
G GSTK1 glutathione S-transferase kappa 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 7:143,263,441...143,269,115
Ensembl chr 7:143,244,093...143,270,854
JBrowse link
G GSTM1 glutathione S-transferase mu 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039
JBrowse link
G GSTM2 glutathione S-transferase mu 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551
JBrowse link
G GSTM4 glutathione S-transferase mu 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 1:109,656,076...109,665,497
Ensembl chr 1:109,656,099...109,674,836
JBrowse link
G HERPUD1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr16:56,932,142...56,944,864
Ensembl chr16:56,932,142...56,944,864
JBrowse link
G HMOX1 heme oxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,207
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
JBrowse link
G HSPB8 heat shock protein family B (small) member 8 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
JBrowse link
G IL10 interleukin 10 decreases abundance ISO IL10 gene mutant form results in decreased abundance of Glycocholic Acid CTD PMID:27580383 NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
JBrowse link
G JUND JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr19:18,279,694...18,281,622
Ensembl chr19:18,279,694...18,281,622
JBrowse link
G MAF MAF bZIP transcription factor multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr16:79,202,624...79,601,952
Ensembl chr16:79,585,843...79,600,737
JBrowse link
G MAFF MAF bZIP transcription factor F multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507
JBrowse link
G MAFG MAF bZIP transcription factor G multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr17:81,918,270...81,927,735
Ensembl chr17:81,918,270...81,927,735
JBrowse link
G MAFK MAF bZIP transcription factor K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr 7:1,530,702...1,543,043
Ensembl chr 7:1,530,702...1,543,043
JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
JBrowse link
G MAP2K1 mitogen-activated protein kinase kinase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,817...66,492,312
Ensembl chr15:66,386,817...66,492,312
JBrowse link
G MAP2K2 mitogen-activated protein kinase kinase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr19:4,090,321...4,124,184
Ensembl chr19:4,090,321...4,124,129
Ensembl chr19:4,090,321...4,124,129
JBrowse link
G MAP2K6 mitogen-activated protein kinase kinase 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865
JBrowse link
G MAPK9 mitogen-activated protein kinase 9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
JBrowse link
G MAPKAPK3 MAPK activated protein kinase 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 3:50,611,877...50,649,291
Ensembl chr 3:50,611,520...50,649,291
JBrowse link
G MGST2 microsomal glutathione S-transferase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 4:139,665,725...139,754,608
Ensembl chr 4:139,665,768...139,740,745
JBrowse link
G MLKL mixed lineage kinase domain like pseudokinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr16:74,671,855...74,700,889
Ensembl chr16:74,671,855...74,700,960
JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
JBrowse link
G NQO2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr 6:2,999,816...3,019,876
Ensembl chr 6:2,987,987...3,021,850
Ensembl chr 6:2,987,987...3,021,850
JBrowse link
G NR1H4 nuclear receptor subfamily 1 group H member 4 increases activity
multiple interactions
EXP Glycocholic Acid results in increased activity of NR1H4 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA
CTD PMID:17567710, PMID:32152650 NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA CTD PMID:32152650 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,485
JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA CTD PMID:32152650 NCBI chr 1:161,229,666...161,238,623
Ensembl chr 1:161,229,666...161,238,302
Ensembl chr 1:161,229,666...161,238,302
JBrowse link
G PIK3C2B phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr 1:204,422,633...204,494,815
Ensembl chr 1:204,422,628...204,494,724
JBrowse link
G PIK3C2G phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 NCBI chr12:18,242,946...18,716,861
Ensembl chr12:18,242,961...18,648,416
Ensembl chr12:18,242,961...18,648,416
JBrowse link
G PIK3C3 phosphatidylinositol 3-kinase catalytic subunit type 3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:41,955,226...42,087,830
Ensembl chr18:41,955,234...42,087,830
JBrowse link
G PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 5:68,215,737...68,301,821
Ensembl chr 5:68,215,756...68,301,821
JBrowse link
G POR cytochrome p450 oxidoreductase decreases abundance ISO POR gene mutant form results in decreased abundance of Glycocholic Acid CTD PMID:25034404 NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855
JBrowse link
G RALA RAS like proto-oncogene A multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr 7:39,622,955...39,708,124
Ensembl chr 7:39,623,565...39,708,120
JBrowse link
G RAP1A RAP1A, member of RAS oncogene family multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 1:111,542,009...111,716,695
Ensembl chr 1:111,542,218...111,716,691
JBrowse link
G RIPK1 receptor interacting serine/threonine kinase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,991...3,115,187
JBrowse link
G RRAS2 RAS related 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr11:14,277,920...14,364,506
Ensembl chr11:14,277,922...14,364,506
JBrowse link
G SCARB1 scavenger receptor class B member 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA CTD PMID:32152650 NCBI chr12:124,776,856...124,863,864
Ensembl chr12:124,776,856...124,882,668
JBrowse link
G SERPINE1 serpin family E member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA CTD PMID:32152650 NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
JBrowse link
G SH3GLB1 SH3 domain containing GRB2 like, endophilin B1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 1:86,704,570...86,748,184
Ensembl chr 1:86,704,570...86,748,184
JBrowse link
G SLC10A1 solute carrier family 10 member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA CTD PMID:32152650 NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
JBrowse link
G SLC51A solute carrier family 51 subunit alpha multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid] CTD PMID:32152650, PMID:32294204 NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178
JBrowse link
G SLC51B solute carrier family 51 subunit beta multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid] CTD PMID:32152650, PMID:32294204 NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397
JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 increases abundance
multiple interactions
EXP SLCO1B1 SNP results in increased abundance of Glycocholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA
CTD PMID:22022402, PMID:32152650 NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein] CTD PMID:22316666, PMID:32152650 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
JBrowse link
G SQSTM1 sequestosome 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
JBrowse link
G STIP1 stress induced phosphoprotein 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr11:64,185,272...64,204,543
Ensembl chr11:64,185,272...64,204,543
JBrowse link
G SULT2A1 sulfotransferase family 2A member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 NCBI chr19:47,870,467...47,886,315
Ensembl chr19:47,870,467...47,886,315
JBrowse link
G UBE2K ubiquitin conjugating enzyme E2 K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr 4:39,698,136...39,782,792
Ensembl chr 4:39,698,109...39,782,792
JBrowse link
G UGT2B4 UDP glucuronosyltransferase family 2 member B4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA CTD PMID:32152650 NCBI chr 4:69,480,165...69,526,014
Ensembl chr 4:69,480,165...69,526,014
JBrowse link
G USP14 ubiquitin specific peptidase 14 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:158,557...214,629
Ensembl chr18:158,383...214,629
JBrowse link
G VCP valosin containing protein multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 9:35,056,064...35,072,625
Ensembl chr 9:35,056,064...35,072,627
JBrowse link
glycodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA CTD PMID:32152650 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCC1 ATP binding cassette subfamily C member 1 multiple interactions EXP Glycodeoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr16:15,949,616...16,143,062
Ensembl chr16:15,949,577...16,143,074
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G ABCC4 ATP binding cassette subfamily C member 4 multiple interactions EXP [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
JBrowse link
G AKR1A1 aldo-keto reductase family 1 member A1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 1:45,550,779...45,570,051
Ensembl chr 1:45,550,543...45,570,049
JBrowse link
G AKR7A2 aldo-keto reductase family 7 member A2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,303,965...19,312,146
JBrowse link
G AKR7A3 aldo-keto reductase family 7 member A3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 NCBI chr 1:19,274,229...19,289,362
Ensembl chr 1:19,282,573...19,288,770
JBrowse link
G AOX1 aldehyde oxidase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 2:200,585,952...200,677,064
Ensembl chr 2:200,586,014...200,677,064
JBrowse link
G ATF4 activating transcription factor 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr22:39,514,494...39,522,686
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
JBrowse link
G ATF6 activating transcription factor 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,320...161,964,070
JBrowse link
G ATG7 autophagy related 7 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 3:11,272,348...11,564,652
Ensembl chr 3:11,272,309...11,557,665
JBrowse link
G CASP3 caspase 3 multiple interactions ISO [Glycodeoxycholic Acid co-treated with Ceruletide] results in decreased activity of CASP3 protein CTD PMID:18832452 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CAT catalase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
JBrowse link
G CBR1 carbonyl reductase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166
JBrowse link
G CCR2 C-C motif chemokine receptor 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 3:46,354,111...46,360,940
Ensembl chr 3:46,353,744...46,360,940
Ensembl chr 3:46,353,744...46,360,940
JBrowse link
G CSF1 colony stimulating factor 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
JBrowse link
G CYLD CYLD lysine 63 deubiquitinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr16:50,742,086...50,801,935
Ensembl chr16:50,742,050...50,801,935
JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA CTD PMID:32152650 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
JBrowse link
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DNAJB1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:14,514,769...14,530,597
Ensembl chr19:14,514,769...14,529,770
JBrowse link
G DNAJB11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr 3:186,570,720...186,585,793
Ensembl chr 3:186,567,403...186,585,800
JBrowse link
G DNAJB6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 7:157,337,004...157,417,439
Ensembl chr 7:157,335,381...157,417,439
JBrowse link
G DNAJB9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850
JBrowse link
G DNAJC1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr10:21,756,548...22,003,763
Ensembl chr10:21,756,548...22,003,769
JBrowse link
G DNAJC10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 2:182,716,257...182,794,464
Ensembl chr 2:182,716,041...182,794,464
JBrowse link
G DNAJC16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 1:15,526,694...15,571,987
Ensembl chr 1:15,526,813...15,592,379
JBrowse link
G DNAJC18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr 5:139,410,203...139,439,525
Ensembl chr 5:139,408,588...139,444,491
JBrowse link
G DNAJC19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 3:180,983,709...180,989,838
Ensembl chr 3:180,983,709...180,989,774
JBrowse link
G DNAJC21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 5:34,929,540...34,958,964
Ensembl chr 5:34,929,559...34,958,964
JBrowse link
G DNAJC3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr13:95,677,139...95,794,988
Ensembl chr13:95,677,139...95,794,988
JBrowse link
G DNAJC6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 1:65,264,749...65,415,871
Ensembl chr 1:65,248,219...65,415,871
JBrowse link
G DNAJC9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr10:73,241,954...73,247,255
Ensembl chr10:73,183,362...73,247,255
Ensembl chr10:73,183,362...73,247,255
JBrowse link
G ENC1 ectodermal-neural cortex 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 5:74,627,409...74,640,728
Ensembl chr 5:74,627,406...74,641,424
JBrowse link
G EPHX1 epoxide hydrolase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,092...225,845,563
JBrowse link
G FKBP5 FKBP prolyl isomerase 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583
JBrowse link
G FMO1 flavin containing dimethylaniline monoxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr 1:171,248,473...171,285,978
Ensembl chr 1:171,248,471...171,285,978
JBrowse link
G FOSL1 FOS like 1, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
JBrowse link
G GPX2 glutathione peroxidase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,905
JBrowse link
G GSTA1 glutathione S-transferase alpha 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA CTD PMID:32152650 NCBI chr 6:52,791,371...52,803,827
Ensembl chr 6:52,791,371...52,803,860
JBrowse link
G GSTA3 glutathione S-transferase alpha 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA CTD PMID:32152650 NCBI chr 6:52,896,646...52,909,799
Ensembl chr 6:52,896,639...52,909,698
JBrowse link
G GSTK1 glutathione S-transferase kappa 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 7:143,263,441...143,269,115
Ensembl chr 7:143,244,093...143,270,854
JBrowse link
G GSTM1 glutathione S-transferase mu 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039
JBrowse link
G GSTM2 glutathione S-transferase mu 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551
JBrowse link
G GSTM4 glutathione S-transferase mu 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 1:109,656,076...109,665,497
Ensembl chr 1:109,656,099...109,674,836
JBrowse link
G HERPUD1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr16:56,932,142...56,944,864
Ensembl chr16:56,932,142...56,944,864
JBrowse link
G HMOX1 heme oxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,207
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
JBrowse link
G HSPB8 heat shock protein family B (small) member 8 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
JBrowse link
G JUND JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr19:18,279,694...18,281,622
Ensembl chr19:18,279,694...18,281,622
JBrowse link
G MAF MAF bZIP transcription factor multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr16:79,202,624...79,601,952
Ensembl chr16:79,585,843...79,600,737
JBrowse link
G MAFF MAF bZIP transcription factor F multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507
JBrowse link
G MAFG MAF bZIP transcription factor G multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr17:81,918,270...81,927,735
Ensembl chr17:81,918,270...81,927,735
JBrowse link
G MAFK MAF bZIP transcription factor K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr 7:1,530,702...1,543,043
Ensembl chr 7:1,530,702...1,543,043
JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
JBrowse link
G MAP2K1 mitogen-activated protein kinase kinase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,817...66,492,312
Ensembl chr15:66,386,817...66,492,312
JBrowse link
G MAP2K2 mitogen-activated protein kinase kinase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr19:4,090,321...4,124,184
Ensembl chr19:4,090,321...4,124,129
Ensembl chr19:4,090,321...4,124,129
JBrowse link
G MAP2K6 mitogen-activated protein kinase kinase 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865
JBrowse link
G MAPK9 mitogen-activated protein kinase 9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
JBrowse link
G MAPKAPK3 MAPK activated protein kinase 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 3:50,611,877...50,649,291
Ensembl chr 3:50,611,520...50,649,291
JBrowse link
G MGST2 microsomal glutathione S-transferase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 4:139,665,725...139,754,608
Ensembl chr 4:139,665,768...139,740,745
JBrowse link
G MLKL mixed lineage kinase domain like pseudokinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr16:74,671,855...74,700,889
Ensembl chr16:74,671,855...74,700,960
JBrowse link
G MYL9 myosin light chain 9 multiple interactions ISO Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein]; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein] CTD PMID:29660437 NCBI chr20:36,541,519...36,551,447
Ensembl chr20:36,541,497...36,551,447
JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
JBrowse link
G NQO2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr 6:2,999,816...3,019,876
Ensembl chr 6:2,987,987...3,021,850
Ensembl chr 6:2,987,987...3,021,850
JBrowse link
G NR1H4 nuclear receptor subfamily 1 group H member 4 increases activity
multiple interactions
EXP Glycodeoxycholic Acid results in increased activity of NR1H4 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA
CTD PMID:17567710, PMID:32152650 NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA CTD PMID:32152650 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,485
JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA CTD PMID:32152650 NCBI chr 1:161,229,666...161,238,623
Ensembl chr 1:161,229,666...161,238,302
Ensembl chr 1:161,229,666...161,238,302
JBrowse link
G PIK3C2B phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr 1:204,422,633...204,494,815
Ensembl chr 1:204,422,628...204,494,724
JBrowse link
G PIK3C2G phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 NCBI chr12:18,242,946...18,716,861
Ensembl chr12:18,242,961...18,648,416
Ensembl chr12:18,242,961...18,648,416
JBrowse link
G PIK3C3 phosphatidylinositol 3-kinase catalytic subunit type 3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:41,955,226...42,087,830
Ensembl chr18:41,955,234...42,087,830
JBrowse link
G PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 5:68,215,737...68,301,821
Ensembl chr 5:68,215,756...68,301,821
JBrowse link
G POR cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of Glycodeoxycholic Acid CTD PMID:25034404 NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855
JBrowse link
G PPP1R12A protein phosphatase 1 regulatory subunit 12A multiple interactions ISO Glycodeoxycholic Acid inhibits the reaction [15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid results in increased phosphorylation of PPP1R12A protein] CTD PMID:29660437 NCBI chr12:79,773,563...79,935,460
Ensembl chr12:79,773,563...79,935,460
JBrowse link
G RALA RAS like proto-oncogene A multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr 7:39,622,955...39,708,124
Ensembl chr 7:39,623,565...39,708,120
JBrowse link
G RAP1A RAP1A, member of RAS oncogene family multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 1:111,542,009...111,716,695
Ensembl chr 1:111,542,218...111,716,691
JBrowse link
G RHOA ras homolog family member A multiple interactions ISO Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein] CTD PMID:29660437 NCBI chr 3:49,359,145...49,411,976
Ensembl chr 3:49,359,145...49,412,998
JBrowse link
G RIPK1 receptor interacting serine/threonine kinase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,991...3,115,187
JBrowse link
G RRAS2 RAS related 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr11:14,277,920...14,364,506
Ensembl chr11:14,277,922...14,364,506
JBrowse link
G SCARB1 scavenger receptor class B member 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA CTD PMID:32152650 NCBI chr12:124,776,856...124,863,864
Ensembl chr12:124,776,856...124,882,668
JBrowse link
G SERPINE1 serpin family E member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA CTD PMID:32152650 NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
JBrowse link
G SH3GLB1 SH3 domain containing GRB2 like, endophilin B1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 1:86,704,570...86,748,184
Ensembl chr 1:86,704,570...86,748,184
JBrowse link
G SLC10A1 solute carrier family 10 member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA CTD PMID:32152650 NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
JBrowse link
G SLC51A solute carrier family 51 subunit alpha multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA CTD PMID:32152650 NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178
JBrowse link
G SLC51B solute carrier family 51 subunit beta multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA CTD PMID:32152650 NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397
JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA CTD PMID:32152650 NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA CTD PMID:32152650 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
JBrowse link
G SQSTM1 sequestosome 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
JBrowse link
G STIP1 stress induced phosphoprotein 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr11:64,185,272...64,204,543
Ensembl chr11:64,185,272...64,204,543
JBrowse link
G SULT2A1 sulfotransferase family 2A member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 NCBI chr19:47,870,467...47,886,315
Ensembl chr19:47,870,467...47,886,315
JBrowse link
G UBE2K ubiquitin conjugating enzyme E2 K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr 4:39,698,136...39,782,792
Ensembl chr 4:39,698,109...39,782,792
JBrowse link
G UGT2B4 UDP glucuronosyltransferase family 2 member B4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA CTD PMID:32152650 NCBI chr 4:69,480,165...69,526,014
Ensembl chr 4:69,480,165...69,526,014
JBrowse link
G USP14 ubiquitin specific peptidase 14 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:158,557...214,629
Ensembl chr18:158,383...214,629
JBrowse link
G VCP valosin containing protein multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 9:35,056,064...35,072,625
Ensembl chr 9:35,056,064...35,072,627
JBrowse link
glycolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HSD11B1 hydroxysteroid 11-beta dehydrogenase 1 decreases abundance ISO HSD11B1 gene mutant form results in decreased abundance of glycolithocholic acid CTD PMID:25061560 NCBI chr 1:209,686,179...209,734,929
Ensembl chr 1:209,686,178...209,734,949
JBrowse link
G POR cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of glycolithocholic acid CTD PMID:25034404 NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855
JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 multiple interactions EXP SLCO1B1 protein binds to and results in increased transport of glycolithocholic acid analog CTD PMID:29933103 NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
JBrowse link
glycoursodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G BAX BCL2 associated X, apoptosis regulator multiple interactions ISO glycoursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] CTD PMID:17881359 NCBI chr19:48,954,825...48,961,798
Ensembl chr19:48,954,815...48,961,798
JBrowse link
G EDN1 endothelin 1 decreases expression EXP glycoursodeoxycholic acid results in decreased expression of EDN1 protein CTD PMID:15556138 NCBI chr 6:12,256,463...12,297,194
Ensembl chr 6:12,290,361...12,297,194
JBrowse link
G SLC4A2 solute carrier family 4 member 2 multiple interactions EXP [glycoursodeoxycholic acid co-treated with Dexamethasone] results in increased expression of SLC4A2 mRNA alternative form CTD PMID:18188457 NCBI chr 7:151,058,200...151,076,527
Ensembl chr 7:151,057,210...151,076,526
JBrowse link
G TP53 tumor protein p53 multiple interactions ISO glycoursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] CTD PMID:17881359 NCBI chr17:7,668,402...7,687,550
Ensembl chr17:7,661,779...7,687,538
Ensembl chr17:7,661,779...7,687,538
JBrowse link
sulfoglycolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLC10A1 solute carrier family 10 member 1 increases uptake EXP SLC10A1 protein results in increased uptake of sulfolithocholylglycine CTD PMID:29024779 NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
JBrowse link
tauro-beta-muricholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 increases expression
multiple interactions
ISO tauromuricholic acid results in increased expression of ABCB11 protein
tauromuricholic acid results in increased expression of and results in increased activity of ABCB11 protein
CTD PMID:11672435, PMID:12644037 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCC2 ATP binding cassette subfamily C member 2 increases expression
multiple interactions
ISO tauromuricholic acid results in increased expression of ABCC2 protein
tauromuricholic acid results in increased expression of and results in increased activity of ABCC2 protein
CTD PMID:11672435, PMID:12644037 NCBI chr10:99,782,602...99,853,741
Ensembl chr10:99,782,640...99,852,594
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 increases expression ISO tauromuricholic acid results in increased expression of ABCC3 protein CTD PMID:11672435 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G AHR aryl hydrocarbon receptor multiple interactions
increases secretion
increases abundance
ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin affects the secretion of tauromuricholic acid]
AHR gene mutant form results in increased secretion of tauromuricholic acid
AHR gene mutant form results in increased abundance of tauromuricholic acid
CTD PMID:29452137, PMID:32679164 NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
JBrowse link
G CXCL1 C-X-C motif chemokine ligand 1 multiple interactions ISO [Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL1 mRNA CTD PMID:22098667 NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308
JBrowse link
G CXCL2 C-X-C motif chemokine ligand 2 multiple interactions ISO [Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL2 mRNA CTD PMID:22098667 NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196
JBrowse link
G FECH ferrochelatase affects abundance ISO FECH protein affects the abundance of tauromuricholic acid CTD PMID:29906468 NCBI chr18:57,544,377...57,586,708
Ensembl chr18:57,544,389...57,586,702
Ensembl chr18:57,544,389...57,586,702
JBrowse link
G ICAM1 intercellular adhesion molecule 1 multiple interactions ISO [Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of ICAM1 mRNA CTD PMID:22098667 NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
JBrowse link
G IL10 interleukin 10 increases abundance ISO IL10 gene mutant form results in increased abundance of tauromuricholic acid CTD PMID:27580383 NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
JBrowse link
G NR1H4 nuclear receptor subfamily 1 group H member 4 affects abundance ISO NR1H4 protein affects the abundance of tauromuricholic acid CTD PMID:30556042 NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
JBrowse link
G PPARA peroxisome proliferator activated receptor alpha multiple interactions
increases abundance
ISO [PPARA gene mutant form results in increased susceptibility to Clofibrate] which results in increased abundance of tauromuricholic acid; PPARA gene mutant form inhibits the reaction [Gemfibrozil results in increased abundance of tauromuricholic acid]
PPARA gene mutant form results in increased abundance of tauromuricholic acid
CTD PMID:24385052, PMID:29175453 NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,756
JBrowse link
G SLC10A2 solute carrier family 10 member 2 increases expression ISO tauromuricholic acid results in increased expression of SLC10A2 protein CTD PMID:11672435 NCBI chr13:103,043,998...103,066,417
Ensembl chr13:103,043,998...103,066,417
JBrowse link
G SMAD3 SMAD family member 3 increases abundance ISO SMAD3 protein results in increased abundance of tauromuricholic acid CTD PMID:23034213 NCBI chr15:67,065,602...67,195,195
Ensembl chr15:67,063,763...67,195,169
JBrowse link
taurochenodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 affects transport
increases expression
ISO ABCB11 protein affects the transport of Taurochenodeoxycholic Acid
Taurochenodeoxycholic Acid results in increased expression of ABCB11 protein
CTD PMID:11343252, PMID:11672435 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCC2 ATP binding cassette subfamily C member 2 increases expression ISO Taurochenodeoxycholic Acid results in increased expression of ABCC2 protein CTD PMID:11672435 NCBI chr10:99,782,602...99,853,741
Ensembl chr10:99,782,640...99,852,594
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 increases expression ISO Taurochenodeoxycholic Acid results in increased expression of ABCC3 protein CTD PMID:11672435 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G AHR aryl hydrocarbon receptor increases secretion
increases abundance
ISO AHR gene mutant form results in increased secretion of Taurochenodeoxycholic Acid
AHR gene mutant form results in increased abundance of Taurochenodeoxycholic Acid
CTD PMID:32679164 NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
JBrowse link
G FECH ferrochelatase affects abundance ISO FECH protein affects the abundance of Taurochenodeoxycholic Acid CTD PMID:29906468 NCBI chr18:57,544,377...57,586,708
Ensembl chr18:57,544,389...57,586,702
Ensembl chr18:57,544,389...57,586,702
JBrowse link
G GSK3B glycogen synthase kinase 3 beta multiple interactions ISO Taurochenodeoxycholic Acid results in increased phosphorylation of and results in decreased activity of GSK3B protein CTD PMID:20512997 NCBI chr 3:119,821,321...120,095,823
Ensembl chr 3:119,821,323...120,094,417
Ensembl chr 3:119,821,323...120,094,417
JBrowse link
G HGF hepatocyte growth factor multiple interactions EXP Taurochenodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] CTD PMID:15802798 NCBI chr 7:81,699,006...81,770,438
Ensembl chr 7:81,699,010...81,770,438
JBrowse link
G IL10 interleukin 10 increases abundance ISO IL10 gene mutant form results in increased abundance of Taurochenodeoxycholic Acid CTD PMID:27580383 NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
JBrowse link
G POR cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of Taurochenodeoxycholic Acid CTD PMID:25034404 NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855
JBrowse link
G SLC10A2 solute carrier family 10 member 2 increases expression ISO Taurochenodeoxycholic Acid results in increased expression of SLC10A2 protein CTD PMID:11672435 NCBI chr13:103,043,998...103,066,417
Ensembl chr13:103,043,998...103,066,417
JBrowse link
G SLC51A solute carrier family 51 subunit alpha multiple interactions EXP [SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid] CTD PMID:32294204 NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178
JBrowse link
G SLC51B solute carrier family 51 subunit beta multiple interactions EXP [SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid] CTD PMID:32294204 NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397
JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 increases abundance
increases transport
EXP SLCO1B1 SNP results in increased abundance of Taurochenodeoxycholic Acid
SLCO1B1 protein results in increased transport of Taurochenodeoxycholic Acid
CTD PMID:22022402, PMID:29933103 NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
JBrowse link
G SMAD3 SMAD family member 3 increases abundance ISO SMAD3 protein results in increased abundance of Taurochenodeoxycholic Acid CTD PMID:23034213 NCBI chr15:67,065,602...67,195,195
Ensembl chr15:67,063,763...67,195,169
JBrowse link
G TGFB1 transforming growth factor beta 1 increases expression ISO Taurochenodeoxycholic Acid results in increased expression of TGFB1 protein CTD PMID:8743917 NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
JBrowse link
G TNF tumor necrosis factor increases expression ISO Taurochenodeoxycholic Acid results in increased expression of TNF protein CTD PMID:8743917 NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
JBrowse link
taurocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCA8 ATP binding cassette subfamily A member 8 affects transport EXP ABCA8 protein affects the transport of Taurocholic Acid CTD PMID:12379217 NCBI chr17:68,867,285...68,955,415
Ensembl chr17:68,867,289...68,955,392
JBrowse link
G ABCB1 ATP binding cassette subfamily B member 1 increases expression ISO Taurocholic Acid results in increased expression of ABCB1 protein
Taurocholic Acid results in increased expression of ABCB1A mRNA
CTD PMID:11113123, PMID:27160211 NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
Ensembl chr 7:87,503,017...87,713,323
JBrowse link
G ABCB11 ATP binding cassette subfamily B member 11 affects import
increases uptake
increases expression
multiple interactions
increases transport
increases export
affects transport
increases import
affects secretion
decreases uptake
EXP
ISO
ABCB11 protein affects the import of Taurocholic Acid
ABCB11 protein results in increased uptake of Taurocholic Acid
Taurocholic Acid results in increased expression of ABCB11 mRNA
2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide inhibits the reaction [ABCB11 protein results in increased import of Taurocholic Acid]; 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Amiodarone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Astemizole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atazanavir Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atenolol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atorvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Atorvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Atropine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Benzbromarone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; bisbenzimide ethoxide trihydrochloride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Bosentan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Budesonide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Calcium deficiency inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]; Cefaclor inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Celecoxib inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; cerivastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; cerivastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; chelerythrine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cholates inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Clarithromycin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Clotrimazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Cyclosporine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Dehydroepiandrosterone Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Diclofenac inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Diethylstilbestrol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Dipyridamole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Disulfiram inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; efavirenz inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Elacridar inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; ergocristine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Erythromycin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ezetimibe inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Felodipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fenofibrate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Floxacillin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fluvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Fluvoxamine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Fusidic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; glimepiride inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glipizide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glyburide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Glycyrrhizic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Imatinib Mesylate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indocyanine Green inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Indomethacin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Isradipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ketoconazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Kynurenic Acid inhibits the reaction [ABCB11 protein results in increased uptake of Taurocholic Acid]; Lopinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Loratadine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Losartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Lovastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Midazolam inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Mifepristone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; morin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Naproxen inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; nefazodone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nelfinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nicardipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nifedipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nitrendipine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Nitrofurantoin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ofloxacin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; olmesartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; pilsicainide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; pitavastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; pitavastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Pravastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Progesterone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ranolazine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; repaglinide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Reserpine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Ritonavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rosiglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Rosuvastatin Calcium inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Saquinavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Silymarin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; simvastatin acid inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Simvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Spironolactone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Sulfamethoxazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Sulfinpyrazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Taurolithocholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Telmisartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Terfenadine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Tinidazole inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; tipranavir inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Troglitazone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; verlukast inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]; Vinblastine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
ABCB11 protein affects the transport of Taurocholic Acid; ABCB11 protein mutant form affects the transport of Taurocholic Acid
Taurocholic Acid results in increased expression of and results in increased activity of ABCB11 protein; troglitazone inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]; troglitazone sulfate inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid]
Taurocholic Acid results in increased expression of ABCB11 protein
ABCB11 protein affects the secretion of Taurocholic Acid
ABCB11 protein results in decreased uptake of Taurocholic Acid
CTD PMID:10617675, PMID:11113123, PMID:11179459, PMID:11557132, PMID:12518026, PMID:12642476, PMID:12644037, PMID:12865277, PMID:14672610, PMID:14724752, PMID:15465654, PMID:15791618, PMID:15901796, PMID:16039748, PMID:19223659, PMID:20147439, PMID:20829430, PMID:24014644, PMID:25862123, PMID:27160211, PMID:27676153, PMID:30639138, PMID:31348918 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCB4 ATP binding cassette subfamily B member 4 increases expression ISO Taurocholic Acid results in increased expression of ABCB4 protein CTD PMID:11113123 NCBI chr 7:87,398,988...87,476,722
Ensembl chr 7:87,401,697...87,480,435
Ensembl chr 7:87,401,697...87,480,435
JBrowse link
G ABCC1 ATP binding cassette subfamily C member 1 multiple interactions EXP Taurocholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr16:15,949,616...16,143,062
Ensembl chr16:15,949,577...16,143,074
JBrowse link
G ABCC2 ATP binding cassette subfamily C member 2 increases activity
increases expression
multiple interactions
ISO Taurocholic Acid results in increased activity of ABCC2 protein; Taurocholic Acid results in increased activity of ABCC2 protein modified form
Taurocholic Acid results in increased expression of ABCC2 mRNA
Taurocholic Acid results in increased expression of and results in increased activity of ABCC2 protein
CTD PMID:12644037, PMID:15904671, PMID:27160211 NCBI chr10:99,782,602...99,853,741
Ensembl chr10:99,782,640...99,852,594
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 increases activity
increases uptake
multiple interactions
affects transport
EXP
ISO
Taurocholic Acid results in increased activity of ABCC3 protein
ABCC3 protein results in increased uptake of Taurocholic Acid
4-cresylglucuronide promotes the reaction [ABCC3 protein results in increased uptake of Taurocholic Acid]; hippuric acid promotes the reaction [ABCC3 protein results in increased uptake of Taurocholic Acid]
ABCC3 protein affects the transport of Taurocholic Acid
CTD PMID:11557524, PMID:17569508, PMID:30639138 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G ABCG2 ATP binding cassette subfamily G member 2 (Junior blood group) increases expression ISO Taurocholic Acid results in increased expression of ABCG2 mRNA CTD PMID:27160211 NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
JBrowse link
G AHR aryl hydrocarbon receptor multiple interactions
increases secretion
ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Taurocholic Acid]
AHR gene mutant form results in increased secretion of Taurocholic Acid
CTD PMID:29452137, PMID:32679164 NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
JBrowse link
G AKT1 AKT serine/threonine kinase 1 multiple interactions ISO Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in decreased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in decreased phosphorylation of AKT1 protein]] CTD PMID:12388182 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
JBrowse link
G APOA1 apolipoprotein A1 decreases expression EXP Taurocholic Acid results in decreased expression of APOA1 protein CTD PMID:19445040 NCBI chr11:116,835,751...116,837,950
Ensembl chr11:116,835,751...116,837,622
Ensembl chr11:116,835,751...116,837,622
JBrowse link
G APOA4 apolipoprotein A4 multiple interactions ISO [Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in increased expression of APOA4 protein CTD PMID:6631239 NCBI chr11:116,820,700...116,823,304
Ensembl chr11:116,820,700...116,823,304
JBrowse link
G APOE apolipoprotein E multiple interactions ISO [Taurocholic Acid co-treated with Triolein co-treated with Lecithins] results in decreased expression of APOE protein CTD PMID:6631239 NCBI chr19:44,905,796...44,909,393
Ensembl chr19:44,905,791...44,909,393
JBrowse link
G BCL2 BCL2 apoptosis regulator multiple interactions
increases expression
EXP sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of BCL2 protein] CTD PMID:18512153 NCBI chr18:63,123,346...63,320,280
Ensembl chr18:63,123,346...63,320,128
JBrowse link
G BLVRA biliverdin reductase A increases expression EXP Taurocholic Acid results in increased expression of BLVRA mRNA CTD PMID:18706437 NCBI chr 7:43,758,122...43,807,342
Ensembl chr 7:43,758,680...43,807,342
JBrowse link
G BNIP3L BCL2 interacting protein 3 like increases expression ISO Taurocholic Acid results in increased expression of BNIP3L mRNA; Taurocholic Acid results in increased expression of BNIP3L protein CTD PMID:14530762 NCBI chr 8:26,383,054...26,413,127
Ensembl chr 8:26,383,054...26,505,636
JBrowse link
G CASP3 caspase 3 multiple interactions ISO Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein] CTD PMID:12388182 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CASP8 caspase 8 multiple interactions ISO Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP8 protein] CTD PMID:12388182 NCBI chr 2:201,233,443...201,287,711
Ensembl chr 2:201,233,443...201,287,711
JBrowse link
G CASP9 caspase 9 multiple interactions ISO Taurocholic Acid inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP9 protein] CTD PMID:12388182 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
JBrowse link
G CAV1 caveolin 1 increases secretion EXP CAV1 protein results in increased secretion of Taurocholic Acid CTD PMID:14647059 NCBI chr 7:116,525,009...116,561,185
Ensembl chr 7:116,525,001...116,561,184
JBrowse link
G CAV2 caveolin 2 increases secretion EXP CAV2 protein results in increased secretion of Taurocholic Acid CTD PMID:14647059 NCBI chr 7:116,499,738...116,508,541
Ensembl chr 7:116,287,380...116,508,541
JBrowse link
G CCL2 C-C motif chemokine ligand 2 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]] CTD PMID:21224055, PMID:28505368 NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,218...34,257,203
JBrowse link
G CCL20 C-C motif chemokine ligand 20 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL20 mRNA] CTD PMID:21224055 NCBI chr 2:227,813,842...227,817,556
Ensembl chr 2:227,805,739...227,817,564
JBrowse link
G CCL3 C-C motif chemokine ligand 3 increases expression ISO Taurocholic Acid results in increased expression of CCL3 mRNA CTD PMID:21224055 NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169
JBrowse link
G CCL4 C-C motif chemokine ligand 4 increases expression ISO Taurocholic Acid results in increased expression of CCL4 mRNA CTD PMID:21224055 NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621
JBrowse link
G CCL5 C-C motif chemokine ligand 5 increases expression ISO Taurocholic Acid results in increased expression of CCL5 mRNA CTD PMID:21224055 NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
JBrowse link
G CCL7 C-C motif chemokine ligand 7 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL7 mRNA] CTD PMID:21224055 NCBI chr17:34,270,221...34,272,242
Ensembl chr17:34,270,221...34,272,242
JBrowse link
G CCND1 cyclin D1 multiple interactions
increases expression
EXP sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 mRNA]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein]
Taurocholic Acid results in increased expression of CCND1 mRNA; Taurocholic Acid results in increased expression of CCND1 protein
CTD PMID:18512153, PMID:18840136 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
JBrowse link
G CCNE1 cyclin E1 multiple interactions
increases expression
EXP sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein] CTD PMID:18512153 NCBI chr19:29,811,991...29,824,312
Ensembl chr19:29,811,991...29,824,312
JBrowse link
G CEL carboxyl ester lipase multiple interactions EXP Taurocholic Acid inhibits the reaction [Polyphenols results in decreased activity of CEL protein] CTD PMID:16099206 NCBI chr 9:133,061,981...133,071,861
Ensembl chr 9:133,061,978...133,071,863
Ensembl chr 9:133,061,978...133,071,863
JBrowse link
G CFTR CF transmembrane conductance regulator affects uptake
increases activity
ISO CFTR protein mutant form affects the uptake of Taurocholic Acid
Taurocholic Acid results in increased activity of CFTR protein
CTD PMID:15099439, PMID:16037545 NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971
Ensembl chr 7:117,287,120...117,715,971
JBrowse link
G CSF2 colony stimulating factor 2 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CSF2 mRNA] CTD PMID:21224055 NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170
JBrowse link
G CSF3 colony stimulating factor 3 increases expression ISO Taurocholic Acid results in increased expression of CSF3 mRNA CTD PMID:21224055 NCBI chr17:40,015,440...40,017,813
Ensembl chr17:40,015,361...40,017,813
JBrowse link
G CXCL1 C-X-C motif chemokine ligand 1 increases expression
multiple interactions
ISO Taurocholic Acid results in increased expression of CXCL1 mRNA
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL1 mRNA; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL1 mRNA]
CTD PMID:21224055, PMID:22098667, PMID:26176423 NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308
JBrowse link
G CXCL10 C-X-C motif chemokine ligand 10 increases expression ISO Taurocholic Acid results in increased expression of CXCL10 mRNA CTD PMID:21224055 NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497
JBrowse link
G CXCL11 C-X-C motif chemokine ligand 11 increases expression ISO Taurocholic Acid results in increased expression of CXCL11 mRNA CTD PMID:21224055 NCBI chr 4:76,033,682...76,036,070
Ensembl chr 4:76,033,682...76,041,415
JBrowse link
G CXCL13 C-X-C motif chemokine ligand 13 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL13 mRNA] CTD PMID:21224055 NCBI chr 4:77,511,753...77,611,834
Ensembl chr 4:77,511,753...77,611,834
JBrowse link
G CXCL16 C-X-C motif chemokine ligand 16 increases expression ISO Taurocholic Acid results in increased expression of CXCL16 mRNA CTD PMID:21224055 NCBI chr17:4,733,533...4,739,928
Ensembl chr17:4,733,533...4,739,928
Ensembl chr17:4,733,533...4,739,928
JBrowse link
G CXCL2 C-X-C motif chemokine ligand 2 increases expression
multiple interactions
ISO Taurocholic Acid results in increased expression of CXCL2 mRNA; Taurocholic Acid results in increased expression of CXCL2 protein
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL2 mRNA; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 protein]
CTD PMID:21224055, PMID:22098667, PMID:26176423 NCBI chr 4:74,097,040...74,099,195
Ensembl chr 4:74,097,040...74,099,196
JBrowse link
G CXCL6 C-X-C motif chemokine ligand 6 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL5 mRNA] CTD PMID:21224055 NCBI chr 4:73,836,678...73,838,760
Ensembl chr 4:73,836,640...73,849,064
JBrowse link
G CYP27A1 cytochrome P450 family 27 subfamily A member 1 decreases expression ISO Taurocholic Acid results in decreased expression of CYP27A1 mRNA CTD PMID:7832767 NCBI chr 2:218,781,733...218,815,293
Ensembl chr 2:218,781,749...218,815,293
JBrowse link
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 multiple interactions
decreases expression
ISO FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA] CTD PMID:7832767, PMID:16284190 NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
JBrowse link
G CYP7B1 cytochrome P450 family 7 subfamily B member 1 decreases activity
decreases expression
ISO Taurocholic Acid results in decreased activity of CYP7B1 protein
Taurocholic Acid results in decreased expression of CYP7B1 mRNA
CTD PMID:12029625 NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737
JBrowse link
G EGFR epidermal growth factor receptor multiple interactions
increases phosphorylation
EXP JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein] CTD PMID:26518876 NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
JBrowse link
G EGR1 early growth response 1 multiple interactions
increases expression
ISO EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL20 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CCL7 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CSF2 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL1 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL13 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of CXCL5 mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; EGR1 promotes the reaction [Taurocholic Acid results in increased expression of VCAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of CXCL2 protein]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 protein]
Taurocholic Acid results in increased expression of EGR1 mRNA; Taurocholic Acid results in increased expression of EGR1 protein
CTD PMID:21224055 NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
JBrowse link
G FECH ferrochelatase affects abundance ISO FECH protein affects the abundance of Taurocholic Acid CTD PMID:29906468 NCBI chr18:57,544,377...57,586,708
Ensembl chr18:57,544,389...57,586,702
Ensembl chr18:57,544,389...57,586,702
JBrowse link
G FGF19 fibroblast growth factor 19 multiple interactions
increases expression
ISO [Taurocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FGF15 mRNA
Taurocholic Acid results in increased expression of FGF15 mRNA
CTD PMID:16284190 NCBI chr11:69,698,238...69,704,022
Ensembl chr11:69,698,238...69,704,022
JBrowse link
G FGFR4 fibroblast growth factor receptor 4 multiple interactions ISO FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA] CTD PMID:16284190 NCBI chr 5:177,086,915...177,098,144
Ensembl chr 5:177,086,905...177,098,144
JBrowse link
G HGF hepatocyte growth factor increases uptake ISO HGF protein results in increased uptake of Taurocholic Acid CTD PMID:18031729 NCBI chr 7:81,699,006...81,770,438
Ensembl chr 7:81,699,010...81,770,438
JBrowse link
G HNF4A hepatocyte nuclear factor 4 alpha increases secretion ISO HNF4A protein results in increased secretion of Taurocholic Acid CTD PMID:27160211 NCBI chr20:44,355,699...44,434,596
Ensembl chr20:44,355,700...44,434,596
JBrowse link
G ICAM1 intercellular adhesion molecule 1 multiple interactions
increases expression
ISO rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of ICAM1 protein]
Taurocholic Acid results in increased expression of ICAM1 mRNA; Taurocholic Acid results in increased expression of ICAM1 protein
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of ICAM1 mRNA; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Taurocholic Acid results in increased expression of ICAM1 protein]
CTD PMID:19237016, PMID:21224055, PMID:22098667, PMID:26176423 NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
JBrowse link
G IL10 interleukin 10 increases expression
increases abundance
ISO Taurocholic Acid results in increased expression of IL10 mRNA
IL10 gene mutant form results in increased abundance of Taurocholic Acid
CTD PMID:21224055, PMID:27580383 NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
JBrowse link
G IL1B interleukin 1 beta increases expression
decreases import
multiple interactions
ISO
EXP
Taurocholic Acid results in increased expression of IL1B mRNA
IL1B protein results in decreased import of Taurocholic Acid
[TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B protein]
Taurocholic Acid results in increased expression of IL1B mRNA; Taurocholic Acid results in increased expression of IL1B protein
EGR1 promotes the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]
CTD PMID:21224055, PMID:25604657, PMID:30876886 NCBI chr 2:112,829,751...112,836,843
Ensembl chr 2:112,829,751...112,836,816
JBrowse link
G IL6 interleukin 6 multiple interactions
decreases import
increases expression
ISO
EXP
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein]; Clodronic Acid inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein]; Edaravone promotes the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]
IL6 protein results in decreased import of Taurocholic Acid
[TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]
Taurocholic Acid results in increased expression of IL6 mRNA; Taurocholic Acid results in increased expression of IL6 protein
CTD PMID:20035747, PMID:20382593, PMID:25604657, PMID:26518876, PMID:30876886 NCBI chr 7:22,725,889...22,732,002
Ensembl chr 7:22,725,884...22,732,002
JBrowse link
G KL klotho multiple interactions ISO Taurocholic Acid inhibits the reaction [KL protein results in increased hydrolysis of Glucuronides] CTD PMID:14701853 NCBI chr13:33,016,063...33,066,143
Ensembl chr13:33,016,423...33,066,143
JBrowse link
G KLF4 Kruppel like factor 4 increases expression ISO Taurocholic Acid results in increased expression of KLF4 mRNA CTD PMID:27151938 NCBI chr 9:107,484,852...107,489,769
Ensembl chr 9:107,484,852...107,490,482
JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta increases expression ISO Taurocholic Acid results in increased expression of MAP1LC3B protein CTD PMID:24189133 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions
increases phosphorylation
EXP JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK1 protein] CTD PMID:26518876 NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,754,500...21,867,680
Ensembl chr22:21,754,500...21,867,680
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions
increases phosphorylation
EXP JTE 013 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein] CTD PMID:18512153, PMID:26518876 NCBI chr16:30,114,105...30,123,309
Ensembl chr16:30,114,105...30,123,506
JBrowse link
G MAPK8 mitogen-activated protein kinase 8 multiple interactions ISO NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK8 protein] CTD PMID:28505368 NCBI chr10:48,306,673...48,439,360
Ensembl chr10:48,306,639...48,439,360
JBrowse link
G MAPK9 mitogen-activated protein kinase 9 multiple interactions ISO NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK9 protein] CTD PMID:28505368 NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
JBrowse link
G MIR1178 microRNA 1178 increases expression EXP Taurocholic Acid results in increased expression of MIR1178 mRNA CTD PMID:28851649 NCBI chr12:119,713,634...119,713,724
Ensembl chr12:119,713,634...119,713,724
JBrowse link
G MIR4717 microRNA 4717 increases expression EXP Taurocholic Acid results in increased expression of MIR4717 mRNA CTD PMID:28851649 NCBI chr16:2,274,620...2,274,691
Ensembl chr16:2,274,620...2,274,691
JBrowse link
G MIR488 microRNA 488 increases expression EXP Taurocholic Acid results in increased expression of MIR488 mRNA CTD PMID:28851649 NCBI chr 1:177,029,363...177,029,445
Ensembl chr 1:177,029,363...177,029,445
JBrowse link
G MIR590 microRNA 590 increases expression EXP Taurocholic Acid results in increased expression of MIR590 mRNA CTD PMID:28851649 NCBI chr 7:74,191,198...74,191,294
Ensembl chr 7:74,191,198...74,191,294
JBrowse link
G MMP2 matrix metallopeptidase 2 multiple interactions
increases expression
EXP JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP2 mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP2 protein]
Taurocholic Acid results in increased expression of MMP2 mRNA; Taurocholic Acid results in increased expression of MMP2 protein
CTD PMID:26518876 NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
JBrowse link
G MMP9 matrix metallopeptidase 9 multiple interactions
increases expression
EXP JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP9 mRNA]; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of MMP9 protein]
Taurocholic Acid results in increased expression of MMP9 mRNA; Taurocholic Acid results in increased expression of MMP9 protein
CTD PMID:26518876 NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
JBrowse link
G MPO myeloperoxidase multiple interactions
increases activity
increases expression
ISO astragaloside A inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein]; Edaravone inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein]
Taurocholic Acid results in increased expression of MPO protein
CTD PMID:16440434, PMID:20035747, PMID:25604657 NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
JBrowse link
G MYC MYC proto-oncogene, bHLH transcription factor increases expression
multiple interactions
EXP
ISO
Taurocholic Acid results in increased expression of MYC protein
[NR1H4 protein affects the susceptibility to Taurocholic Acid] which affects the expression of MYC mRNA
Taurocholic Acid results in increased expression of MYC mRNA
sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of MYC protein]
CTD PMID:18512153, PMID:27151938, PMID:30556042 NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
JBrowse link
G NANOG Nanog homeobox increases expression ISO Taurocholic Acid results in increased expression of NANOG mRNA CTD PMID:27151938 NCBI chr12:7,789,402...7,799,146
Ensembl chr12:7,787,794...7,799,146
JBrowse link
G NFE2L2 nuclear factor, erythroid 2 like 2 increases expression ISO Taurocholic Acid results in increased expression of NFE2L2 mRNA CTD PMID:27160211 NCBI chr 2:177,230,303...177,265,131
Ensembl chr 2:177,227,595...177,392,697
JBrowse link
G NFKBIA NFKB inhibitor alpha multiple interactions
decreases expression
ISO astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA protein]
Taurocholic Acid results in decreased expression of NFKBIA mRNA; Taurocholic Acid results in decreased expression of NFKBIA protein
CTD PMID:25604657 NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,511...35,404,749
Ensembl chr14:35,401,511...35,404,749
JBrowse link
G NFKBIB NFKB inhibitor beta multiple interactions
decreases expression
ISO astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB protein]
Taurocholic Acid results in decreased expression of NFKBIB mRNA; Taurocholic Acid results in decreased expression of NFKBIB protein
CTD PMID:25604657 NCBI chr19:38,899,503...38,908,894
Ensembl chr19:38,899,700...38,908,893
JBrowse link
G NOS2 nitric oxide synthase 2 multiple interactions
increases expression
ISO [Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; resveratrol inhibits the reaction [[Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] CTD PMID:16389574 NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
JBrowse link
G NR0B2 nuclear receptor subfamily 0 group B member 2 increases expression EXP Taurocholic Acid results in increased expression of NR0B2 mRNA CTD PMID:18706437 NCBI chr 1:26,911,489...26,914,110
Ensembl chr 1:26,911,489...26,913,975
JBrowse link
G NR1H4 nuclear receptor subfamily 1 group H member 4 multiple interactions
affects response to substance
affects abundance
increases expression
increases export
increases activity
EXP
ISO
epiallopregnanolone sulfate inhibits the reaction [NR1H4 protein results in increased export of Taurocholic Acid]; GW 4064 promotes the reaction [NR1H4 protein results in increased export of Taurocholic Acid]; Taurocholic Acid binds to and results in increased activity of NR1H4 protein
NR1H4 protein affects the susceptibility to Taurocholic Acid
NR1H4 protein affects the abundance of Taurocholic Acid
Taurocholic Acid results in increased expression of NR1H4 mRNA
Taurocholic Acid results in increased activity of NR1H4 protein
[NR1H4 protein affects the susceptibility to Taurocholic Acid] which affects the expression of MYC mRNA; [Taurocholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FGF15 mRNA; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of SERPINE1 mRNA]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK8 protein]; NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased phosphorylation of MAPK9 protein]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA]; pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]]
CTD PMID:16284190, PMID:17567710, PMID:18706437, PMID:19445040, PMID:22961653, PMID:27160211, PMID:28505368, PMID:30556042 NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 increases expression EXP
ISO
Taurocholic Acid results in increased expression of NR1I2 mRNA CTD PMID:18706437, PMID:27160211 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,485
JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 multiple interactions
increases expression
ISO [1,4-bis(2-(3,5-dichloropyridyloxy))benzene binds to and affects the activity of NR1I3 protein] which results in decreased abundance of Taurocholic Acid
Taurocholic Acid results in increased expression of NR1I3 mRNA
CTD PMID:26984780, PMID:27160211 NCBI chr 1:161,229,666...161,238,623
Ensembl chr 1:161,229,666...161,238,302
Ensembl chr 1:161,229,666...161,238,302
JBrowse link
G PNLIP pancreatic lipase increases activity
multiple interactions
ISO Taurocholic Acid results in increased activity of PNLIP protein
orlistat inhibits the reaction [Taurocholic Acid results in increased activity of PNLIP protein]
CTD PMID:11668201 NCBI chr10:116,545,931...116,567,855
Ensembl chr10:116,545,931...116,567,855
JBrowse link
G PON1 paraoxonase 1 multiple interactions
decreases expression
ISO FGFR4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA]; NR1H4 protein affects the reaction [Taurocholic Acid results in decreased expression of PON1 mRNA] CTD PMID:16284190 NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532
JBrowse link
G POR cytochrome p450 oxidoreductase decreases abundance ISO POR gene mutant form results in decreased abundance of Taurocholic Acid CTD PMID:25034404 NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855
JBrowse link
G POU5F1 POU class 5 homeobox 1 increases expression ISO Taurocholic Acid results in increased expression of POU5F1 mRNA CTD PMID:27151938 NCBI chr 6:31,164,337...31,170,682
Ensembl chr 6:31,164,337...31,180,731
JBrowse link
G PPARA peroxisome proliferator activated receptor alpha decreases abundance ISO PPARA gene mutant form results in decreased abundance of Taurocholic Acid CTD PMID:29175453 NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,756
JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO
EXP
Taurocholic Acid results in increased expression of PTGS2 mRNA
Taurocholic Acid results in increased expression of PTGS2 protein
JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; MK 2206 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; U 0126 inhibits the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]
CTD PMID:21224055, PMID:26518876 NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,423
JBrowse link
G RAB7A RAB7A, member RAS oncogene family decreases expression ISO Taurocholic Acid results in decreased expression of RAB7 protein CTD PMID:24189133 NCBI chr 3:128,726,183...128,814,798
Ensembl chr 3:128,693,669...128,825,942
Ensembl chr 3:128,693,669...128,825,942
Ensembl chr 3:128,693,669...128,825,942
JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit multiple interactions
increases phosphorylation
affects localization
ISO
EXP
astragaloside A inhibits the reaction [Taurocholic Acid affects the localization of RELA protein]
Taurocholic Acid results in increased phosphorylation of RELA protein
Taurocholic Acid affects the localization of RELA protein modified form
JTE 013 inhibits the reaction [Taurocholic Acid affects the localization of RELA protein modified form]
CTD PMID:25604657, PMID:26518876 NCBI chr11:65,653,601...65,662,946
Ensembl chr11:65,653,597...65,663,090
JBrowse link
G S1PR2 sphingosine-1-phosphate receptor 2 multiple interactions EXP S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased expression of PTGS2 protein]; S1PR2 mRNA promotes the reaction [Taurocholic Acid results in increased phosphorylation of EGFR protein]; Taurocholic Acid results in increased activity of and results in increased uptake of S1PR2 protein CTD PMID:26518876 NCBI chr19:10,221,433...10,231,331
Ensembl chr19:10,221,433...10,231,331
JBrowse link
G SERPINE1 serpin family E member 1 multiple interactions ISO NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of SERPINE1 mRNA] CTD PMID:28505368 NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
JBrowse link
G SLC10A1 solute carrier family 10 member 1 multiple interactions
increases expression
increases transport
increases import
increases uptake
ISO
EXP
Bile Acids and Salts inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]
Taurocholic Acid results in increased expression of SLC10A1 mRNA
SLC10A1 protein results in increased transport of Taurocholic Acid
SLC10A1 protein results in increased import of Taurocholic Acid
4-cresol sulfate inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; [Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid; Acetamides analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Acetanilides analog promotes the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Anthraquinones analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Benzenesulfonates analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Bile Acids and Salts inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; bisphenol A inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; bisphenol F inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; Fusidic Acid inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Piperazines analog promotes the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Sodium deficiency inhibits the reaction [SLC10A1 protein results in increased import of Taurocholic Acid]; Sulfobromophthalein inhibits the reaction [SLC10A1 protein results in increased uptake of Taurocholic Acid]; Taurocholic Acid inhibits the reaction [SLC10A1 protein results in increased transport of daidzein metabolite]; tetrabromobisphenol A inhibits the reaction [[Sodium co-treated with SLC10A1 protein] results in increased uptake of Taurocholic Acid]; tetrahydrophthalamic acid analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid]; Tobacco Smoke Pollution inhibits the reaction [SLC10A1 protein results in increased import of Taurocholic Acid]
CTD PMID:19464309, PMID:22641618, PMID:23850984, PMID:25106415, PMID:25319728, PMID:25862123, PMID:27160211, PMID:27450509, PMID:27676153, PMID:27989701, PMID:29024779, PMID:30639138 NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
JBrowse link
G SLC10A2 solute carrier family 10 member 2 multiple interactions
increases transport
increases uptake
ISO
EXP
Bile Acids and Salts inhibits the reaction [SLC10A2 protein results in increased uptake of Taurocholic Acid]
Chenodeoxycholic Acid inhibits the reaction [SLC10A2 protein results in increased transport of Taurocholic Acid]
CTD PMID:19464309, PMID:25466967 NCBI chr13:103,043,998...103,066,417
Ensembl chr13:103,043,998...103,066,417
JBrowse link
G SLC19A1 solute carrier family 19 member 1 multiple interactions
decreases activity
ISO Taurocholic Acid inhibits the reaction [SLC19A1 protein affects the transport of Methotrexate]
Taurocholic Acid results in decreased activity of SLC19A1 protein
CTD PMID:14612385 NCBI chr21:45,502,517...45,563,140
Ensembl chr21:45,493,572...45,573,365
JBrowse link
G SLC22A6 solute carrier family 22 member 6 multiple interactions EXP Taurocholic Acid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] CTD PMID:11602689 NCBI chr11:62,976,597...62,984,967
Ensembl chr11:62,936,385...62,984,967
Ensembl chr11:62,936,385...62,984,967
JBrowse link
G SLC22A8 solute carrier family 22 member 8 affects transport EXP SLC22A8 protein affects the transport of Taurocholic Acid CTD PMID:11306713 NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841
JBrowse link
G SLC23A1 solute carrier family 23 member 1 increases expression EXP Taurocholic Acid results in increased expression of SLC23A1 mRNA CTD PMID:18706437 NCBI chr 5:139,367,196...139,384,553
Ensembl chr 5:139,367,196...139,384,553
JBrowse link
G SLC23A2 solute carrier family 23 member 2 increases expression EXP Taurocholic Acid results in increased expression of SLC23A2 mRNA CTD PMID:18706437 NCBI chr20:4,852,358...5,010,313
Ensembl chr20:4,852,356...5,010,293
JBrowse link
G SLC51A solute carrier family 51 subunit alpha multiple interactions EXP [SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid] CTD PMID:32294204 NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178
JBrowse link
G SLC51B solute carrier family 51 subunit beta multiple interactions EXP [SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid] CTD PMID:32294204 NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397
JBrowse link
G SLCO1A2 solute carrier organic anion transporter family member 1A2 affects uptake
increases uptake
multiple interactions
increases expression
affects transport
ISO SLCO1A4 protein affects the uptake of Taurocholic Acid
SLCO1A2 protein results in increased uptake of Taurocholic Acid
Bile Acids and Salts inhibits the reaction [SLCO1A2 protein results in increased uptake of Taurocholic Acid]
Taurocholic Acid results in increased expression of SLCO1A4 mRNA
SLCO1A4 protein affects the transport of Taurocholic Acid
CTD PMID:19464309, PMID:19833843, PMID:21561886, PMID:27160211 NCBI chr12:21,264,600...21,403,663
Ensembl chr12:21,264,600...21,419,594
JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 increases abundance
increases transport
increases import
increases uptake
multiple interactions
EXP SLCO1B1 SNP results in increased abundance of Taurocholic Acid
SLCO1B1 protein results in increased transport of Taurocholic Acid
SLCO1B1 protein results in increased import of Taurocholic Acid
SLCO1B1 protein results in increased uptake of Taurocholic Acid
4-cresol sulfate promotes the reaction [SLCO1B1 protein results in increased uptake of Taurocholic Acid]; Bile Acids and Salts inhibits the reaction [SLCO1B1 protein results in increased uptake of Taurocholic Acid]; Rifampin inhibits the reaction [SLCO1B1 protein results in increased import of Taurocholic Acid]; SLCO1B1 protein binds to and results in increased uptake of Taurocholic Acid; Taurocholic Acid inhibits the reaction [SLCO1B1 protein results in increased susceptibility to cyanoginosin LR]; Taurocholic Acid inhibits the reaction [SLCO1B1 protein results in increased susceptibility to Okadaic Acid]
CTD PMID:16479312, PMID:19464309, PMID:22022402, PMID:26134461, PMID:29933103, PMID:30639138, PMID:31254566 NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
JBrowse link
G SLCO1B3 solute carrier organic anion transporter family member 1B3 increases uptake
increases expression
multiple interactions
EXP
ISO
SLCO1B3 protein results in increased uptake of Taurocholic Acid
Taurocholic Acid results in increased expression of SLCO1B2 mRNA
Bile Acids and Salts inhibits the reaction [SLCO1B3 protein results in increased uptake of Taurocholic Acid]
Taurocholic Acid inhibits the reaction [SLCO1B3 protein results in increased susceptibility to cyanoginosin LR]; Taurocholic Acid inhibits the reaction [SLCO1B3 protein results in increased susceptibility to Okadaic Acid]
CTD PMID:19464309, PMID:26134461, PMID:27160211, PMID:30639138 NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911
JBrowse link
G SLCO2B1 solute carrier organic anion transporter family member 2B1 multiple interactions
increases uptake
EXP Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of Taurocholic Acid] CTD PMID:24285294 NCBI chr11:75,151,107...75,206,549
Ensembl chr11:75,100,563...75,206,549
JBrowse link
G SOD1 superoxide dismutase 1 multiple interactions
decreases expression
ISO astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 protein]
Taurocholic Acid results in decreased expression of SOD1 mRNA; Taurocholic Acid results in decreased expression of SOD1 protein
CTD PMID:25604657 NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,622...31,668,931
Ensembl chr21:31,659,622...31,668,931
JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions
increases expression
decreases expression
EXP
ISO
[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]
Taurocholic Acid results in increased expression of SOD2 mRNA
astragaloside A promotes the reaction [Taurocholic Acid results in decreased expression of SOD2 protein]; astragaloside A promotes the reaction [Taurocholic Acid results in increased expression of SOD2 mRNA]
CTD PMID:22316666, PMID:25604657 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
JBrowse link
G SORT1 sortilin 1 increases sulfation ISO SORT1 gene mutant form results in increased sulfation of Taurocholic Acid CTD PMID:28453831 NCBI chr 1:109,309,575...109,397,940
Ensembl chr 1:109,309,568...109,397,918
JBrowse link
G SOX2 SRY-box transcription factor 2 increases expression ISO Taurocholic Acid results in increased expression of SOX2 mRNA CTD PMID:27151938 NCBI chr 3:181,711,925...181,714,436
Ensembl chr 3:181,711,925...181,714,436
JBrowse link
G SQSTM1 sequestosome 1 increases expression ISO Taurocholic Acid results in increased expression of SQSTM1 protein CTD PMID:24189133 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
JBrowse link
G STAT1 signal transducer and activator of transcription 1 increases phosphorylation
multiple interactions
ISO Taurocholic Acid results in increased phosphorylation of STAT1 protein
rosiglitazone inhibits the reaction [Taurocholic Acid results in increased phosphorylation of STAT1 protein]
CTD PMID:19563079 NCBI chr 2:190,968,989...191,014,197
Ensembl chr 2:190,908,460...191,020,960
Ensembl chr 2:190,908,460...191,020,960
JBrowse link
G STAT3 signal transducer and activator of transcription 3 multiple interactions
increases phosphorylation
EXP sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of STAT3 protein] CTD PMID:18512153 NCBI chr17:42,313,324...42,388,502
Ensembl chr17:42,313,324...42,388,482
Ensembl chr17:42,313,324...42,388,482
JBrowse link
G TNF tumor necrosis factor multiple interactions
decreases import
increases expression
ISO
EXP
astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Clodronic Acid inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Edaravone promotes the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Resveratrol inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein]; Rosiglitazone inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]
TNF protein results in decreased import of Taurocholic Acid
[TNF protein co-treated with IL6 protein co-treated with IL1B protein] results in decreased import of Taurocholic Acid; JTE 013 inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]
Taurocholic Acid results in increased expression of TNF mRNA; Taurocholic Acid results in increased expression of TNF protein
CTD PMID:16389574, PMID:19080501, PMID:19237016, PMID:19563079, PMID:20035747, PMID:20382593, PMID:25604657, PMID:26518876, PMID:30876886 NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
JBrowse link
G VCAM1 vascular cell adhesion molecule 1 multiple interactions
decreases expression
increases expression
ISO
EXP
EGR1 promotes the reaction [Taurocholic Acid results in increased expression of VCAM1 mRNA]
Taurocholic Acid results in decreased expression of VCAM1 protein
CTD PMID:21224055, PMID:26176423, PMID:28851649 NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045
JBrowse link
taurodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 multiple interactions
increases abundance
EXP
ISO
[Glyburide results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [Ketoconazole results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [troglitazone results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid
ABCB11 protein results in increased abundance of Taurodeoxycholic Acid
[Cyclosporine results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [Glyburide results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid; [troglitazone results in decreased activity of ABCB11 protein] which results in decreased export of Taurodeoxycholic Acid
CTD PMID:14570929, PMID:20147439 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCC1 ATP binding cassette subfamily C member 1 multiple interactions EXP Taurodeoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr16:15,949,616...16,143,062
Ensembl chr16:15,949,577...16,143,074
JBrowse link
G AHR aryl hydrocarbon receptor multiple interactions
increases secretion
ISO AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Taurodeoxycholic Acid]
AHR gene mutant form results in increased secretion of Taurodeoxycholic Acid
CTD PMID:29452137, PMID:32679164 NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
JBrowse link
G CASP3 caspase 3 increases activity
multiple interactions
EXP Taurodeoxycholic Acid results in increased activity of CASP3 protein
tauroursodeoxycholic acid inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP3 protein]
CTD PMID:12773247 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CASP9 caspase 9 increases activity
multiple interactions
EXP Taurodeoxycholic Acid results in increased activity of CASP9 protein
tauroursodeoxycholic acid inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP9 protein]
CTD PMID:12773247 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
JBrowse link
G CHRM3 cholinergic receptor muscarinic 3 increases response to substance
increases activity
ISO CHRM3 protein results in increased susceptibility to Taurodeoxycholic Acid
Taurodeoxycholic Acid results in increased activity of CHRM3 protein
CTD PMID:15964566 NCBI chr 1:239,386,565...239,915,450
Ensembl chr 1:239,386,565...239,915,452
JBrowse link
G CYP7B1 cytochrome P450 family 7 subfamily B member 1 decreases activity
decreases expression
ISO Taurodeoxycholic Acid results in decreased activity of CYP7B1 protein
Taurodeoxycholic Acid results in decreased expression of CYP7B1 mRNA
CTD PMID:12029625 NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737
JBrowse link
G IL10 interleukin 10 multiple interactions
increases abundance
ISO Taurodeoxycholic Acid promotes the reaction [irinotecan results in decreased secretion of IL10 protein]
IL10 gene mutant form results in increased abundance of Taurodeoxycholic Acid
CTD PMID:26706406, PMID:27580383 NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
JBrowse link
G MAPK14 mitogen-activated protein kinase 14 increases activity EXP Taurodeoxycholic Acid results in increased activity of MAPK14 protein CTD PMID:14762791 NCBI chr 6:36,027,711...36,122,964
Ensembl chr 6:36,027,677...36,111,236
JBrowse link
G NR1H4 nuclear receptor subfamily 1 group H member 4 increases activity EXP Taurodeoxycholic Acid results in increased activity of NR1H4 protein CTD PMID:17567710 NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
JBrowse link
G PNLIP pancreatic lipase affects folding EXP Taurodeoxycholic Acid affects the folding of PNLIP protein CTD PMID:19346257 NCBI chr10:116,545,931...116,567,855
Ensembl chr10:116,545,931...116,567,855
JBrowse link
G POR cytochrome p450 oxidoreductase affects abundance ISO POR gene mutant form affects the abundance of Taurodeoxycholic Acid CTD PMID:25034404 NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855
JBrowse link
G STIM1 stromal interaction molecule 1 multiple interactions
affects localization
ISO STIM1 protein promotes the reaction [Taurodeoxycholic Acid results in increased abundance of Calcium]
Taurodeoxycholic Acid affects the localization of STIM1 protein
CTD PMID:18342630 NCBI chr11:3,854,604...4,093,210
Ensembl chr11:3,854,527...4,093,210
JBrowse link
taurohyodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AHR aryl hydrocarbon receptor increases secretion ISO AHR gene mutant form results in increased secretion of taurohyodeoxycholic acid CTD PMID:32679164 NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
JBrowse link
taurolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 affects localization
decreases activity
multiple interactions
ISO
EXP
Taurolithocholic Acid affects the localization of ABCB11 protein
Taurolithocholic Acid results in decreased activity of ABCB11 protein
Taurolithocholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Taurolithocholic Acid affects the localization of and affects the activity of ABCB11 protein
CTD PMID:12865277, PMID:15763547, PMID:24014644 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCC2 ATP binding cassette subfamily C member 2 multiple interactions
affects localization
ISO 3-chloroacetylindole inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; [Colchicine co-treated with JTE 013] inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; CYM-5520 inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; Dideoxyadenosine inhibits the reaction [Taurolithocholic Acid affects the localization of ABCC2 protein]; Dideoxyadenosine inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; JTE 013 inhibits the reaction [Taurolithocholic Acid affects the localization of ABCC2 protein]; JTE 013 inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; JTE 013 inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; RMI 12330A inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein]; S1PR2 protein affects the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein; Wortmannin inhibits the reaction [Taurolithocholic Acid results in decreased activity of and affects the localization of ABCC2 protein] CTD PMID:31300867 NCBI chr10:99,782,602...99,853,741
Ensembl chr10:99,782,640...99,852,594
JBrowse link
G AKT1 AKT serine/threonine kinase 1 increases phosphorylation
multiple interactions
ISO Taurolithocholic Acid results in increased phosphorylation of AKT1 protein
JTE 013 inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; KT 5720 inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; RMI 12330A inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; S1PR2 protein affects the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]; Wortmannin inhibits the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein]
CTD PMID:31300867 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
JBrowse link
G CHRM3 cholinergic receptor muscarinic 3 multiple interactions
affects binding
EXP [Taurolithocholic Acid binds to and affects the activity of CHRM3 protein] which results in increased abundance of Inositol Phosphates; Taurolithocholic Acid binds to and affects the activity of CHRM3 protein
Taurolithocholic Acid binds to CHRM3 protein
CTD PMID:12379313, PMID:12464352 NCBI chr 1:239,386,565...239,915,450
Ensembl chr 1:239,386,565...239,915,452
JBrowse link
G FOS Fos proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions
EXP Taurolithocholic Acid results in increased expression of FOS mRNA
tauroursodeoxycholic acid inhibits the reaction [Taurolithocholic Acid results in increased expression of FOS mRNA]
CTD PMID:18164257 NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
JBrowse link
G HSD11B1 hydroxysteroid 11-beta dehydrogenase 1 increases abundance ISO HSD11B1 gene mutant form results in increased abundance of Taurolithocholic Acid CTD PMID:25061560 NCBI chr 1:209,686,179...209,734,929
Ensembl chr 1:209,686,178...209,734,949
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions
EXP Taurolithocholic Acid results in increased expression of JUN mRNA
tauroursodeoxycholic acid inhibits the reaction [Taurolithocholic Acid results in increased expression of JUN mRNA]
CTD PMID:18164257 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
JBrowse link
G POR cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of Taurolithocholic Acid CTD PMID:25034404 NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855
JBrowse link
G PRKACA protein kinase cAMP-activated catalytic subunit alpha multiple interactions
increases activity
ISO JTE 013 inhibits the reaction [Taurolithocholic Acid results in increased activity of PRKACA protein]; KT 5720 inhibits the reaction [Taurolithocholic Acid results in increased activity of PRKACA protein]; RMI 12330A inhibits the reaction [Taurolithocholic Acid results in increased activity of PRKACA protein] CTD PMID:31300867 NCBI chr19:14,091,688...14,117,762
Ensembl chr19:14,091,688...14,118,084
JBrowse link
G S1PR2 sphingosine-1-phosphate receptor 2 multiple interactions ISO S1PR2 protein affects the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; S1PR2 protein affects the reaction [Taurolithocholic Acid results in increased phosphorylation of AKT1 protein] CTD PMID:31300867 NCBI chr19:10,221,433...10,231,331
Ensembl chr19:10,221,433...10,231,331
JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 increases abundance
multiple interactions
EXP SLCO1B1 SNP results in increased abundance of Taurolithocholic Acid
[SLCO1B1 SNP results in increased abundance of Taurolithocholic Acid] which results in increased susceptibility to Simvastatin
CTD PMID:22022402 NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
JBrowse link
G SMAD3 SMAD family member 3 increases abundance ISO SMAD3 protein results in increased abundance of Taurolithocholic Acid CTD PMID:23034213 NCBI chr15:67,065,602...67,195,195
Ensembl chr15:67,063,763...67,195,169
JBrowse link
taurolithocholic acid sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AGT angiotensinogen multiple interactions
decreases response to substance
ISO AGT protein inhibits the reaction [taurolithocholic acid 3-sulfate results in increased activity of CASP3 protein]
AGT protein results in decreased susceptibility to taurolithocholic acid 3-sulfate
CTD PMID:23300732 NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,702,523...230,714,122
JBrowse link
G CASP3 caspase 3 multiple interactions
increases activity
ISO AGT protein inhibits the reaction [taurolithocholic acid 3-sulfate results in increased activity of CASP3 protein] CTD PMID:23300732 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CFTR CF transmembrane conductance regulator decreases activity EXP taurolithocholic acid 3-sulfate results in decreased activity of CFTR protein CTD PMID:15634668 NCBI chr 7:117,480,025...117,668,665
Ensembl chr 7:117,287,120...117,715,971
Ensembl chr 7:117,287,120...117,715,971
JBrowse link
G CHRM1 cholinergic receptor muscarinic 1 affects binding EXP taurolithocholic acid 3-sulfate binds to CHRM1 protein CTD PMID:12464352 NCBI chr11:62,908,675...62,921,861
Ensembl chr11:62,908,679...62,921,807
JBrowse link
G IFNG interferon gamma multiple interactions
increases expression
ISO Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IFNG mRNA] CTD PMID:22517774 NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
JBrowse link
G IL6 interleukin 6 multiple interactions
increases expression
ISO Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IL6 mRNA] CTD PMID:22517774 NCBI chr 7:22,725,889...22,732,002
Ensembl chr 7:22,725,884...22,732,002
JBrowse link
tauroursodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A2M alpha-2-macroglobulin decreases expression ISO tauroursodeoxycholic acid results in decreased expression of A2M mRNA CTD PMID:15885361 NCBI chr12:9,067,708...9,116,229
Ensembl chr12:9,067,664...9,116,229
JBrowse link
G AADAT aminoadipate aminotransferase decreases expression ISO tauroursodeoxycholic acid results in decreased expression of AADAT mRNA CTD PMID:15885361 NCBI chr 4:170,060,222...170,091,699
Ensembl chr 4:170,060,222...170,091,699
JBrowse link
G AATF apoptosis antagonizing transcription factor increases expression ISO tauroursodeoxycholic acid results in increased expression of AATF mRNA CTD PMID:15885361 NCBI chr17:36,948,954...37,056,871
Ensembl chr17:36,948,954...37,056,871
JBrowse link
G ABCB11 ATP binding cassette subfamily B member 11 decreases expression
multiple interactions
increases expression
ISO tauroursodeoxycholic acid results in decreased expression of ABCB11 mRNA
tauroursodeoxycholic acid results in increased expression of and results in increased activity of ABCB11 protein
tauroursodeoxycholic acid results in increased expression of ABCB11 protein
CTD PMID:11672435, PMID:12644037, PMID:15885361 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCC1 ATP binding cassette subfamily C member 1 multiple interactions EXP tauroursodeoxycholic acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr16:15,949,616...16,143,062
Ensembl chr16:15,949,577...16,143,074
JBrowse link
G ABCC2 ATP binding cassette subfamily C member 2 multiple interactions
increases expression
ISO tauroursodeoxycholic acid results in increased expression of and results in increased activity of ABCC2 protein
tauroursodeoxycholic acid results in increased expression of ABCC2 protein
CTD PMID:11672435, PMID:12644037 NCBI chr10:99,782,602...99,853,741
Ensembl chr10:99,782,640...99,852,594
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 increases expression ISO tauroursodeoxycholic acid results in increased expression of ABCC3 protein CTD PMID:11672435 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G ACLY ATP citrate lyase decreases expression ISO tauroursodeoxycholic acid results in decreased expression of ACLY mRNA CTD PMID:15885361 NCBI chr17:41,866,916...41,930,542
Ensembl chr17:41,866,917...41,930,542
JBrowse link
G ACSL1 acyl-CoA synthetase long chain family member 1 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of ACSL1 mRNA CTD PMID:15885361 NCBI chr 4:184,755,595...184,826,593
Ensembl chr 4:184,755,595...184,826,818
JBrowse link
G ACTN1 actinin alpha 1 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of ACTN1 mRNA CTD PMID:15885361 NCBI chr14:68,874,123...68,979,302
Ensembl chr14:68,874,128...68,979,440
Ensembl chr14:68,874,128...68,979,440
JBrowse link
G ADH1C alcohol dehydrogenase 1C (class I), gamma polypeptide decreases expression ISO tauroursodeoxycholic acid results in decreased expression of ADH1 mRNA CTD PMID:15885361 NCBI chr 4:99,336,497...99,352,746
Ensembl chr 4:99,336,497...99,352,746
JBrowse link
G ADK adenosine kinase decreases expression ISO tauroursodeoxycholic acid results in decreased expression of ADK mRNA CTD PMID:15885361 NCBI chr10:74,151,185...74,709,300
Ensembl chr10:74,151,202...74,709,963
JBrowse link
G AGT angiotensinogen decreases expression
multiple interactions
ISO tauroursodeoxycholic acid results in decreased expression of AGT mRNA
tauroursodeoxycholic acid inhibits the reaction [AGT protein promotes the reaction [SREBF1 protein binds to TGFB1 promoter]]; tauroursodeoxycholic acid inhibits the reaction [AGT protein results in increased expression of FN1 protein]; tauroursodeoxycholic acid inhibits the reaction [AGT protein results in increased expression of TGFB1 mRNA]; tauroursodeoxycholic acid inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; tauroursodeoxycholic acid inhibits the reaction [AGT protein results in increased secretion of TGFB1 protein]
CTD PMID:15885361, PMID:25398788 NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,702,523...230,714,122
JBrowse link
G AHR aryl hydrocarbon receptor increases abundance
increases secretion
ISO AHR gene mutant form results in increased abundance of tauroursodeoxycholic acid
AHR gene mutant form results in increased secretion of tauroursodeoxycholic acid
CTD PMID:32679164 NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
JBrowse link
G AKR1D1 aldo-keto reductase family 1 member D1 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of AKR1D1 mRNA CTD PMID:15885361 NCBI chr 7:138,076,459...138,118,305
Ensembl chr 7:138,002,324...138,118,305
JBrowse link
G AKT1 AKT serine/threonine kinase 1 multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; tauroursodeoxycholic acid results in increased phosphorylation of and results in increased activity of AKT1 protein CTD PMID:12721362, PMID:25398788 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
JBrowse link
G AMY2B amylase alpha 2B decreases expression ISO tauroursodeoxycholic acid results in decreased expression of AMY1A mRNA CTD PMID:15885361 NCBI chr 1:103,554,644...103,579,534
Ensembl chr 1:103,553,815...103,579,534
JBrowse link
G APAF1 apoptotic peptidase activating factor 1 affects expression
decreases expression
ISO tauroursodeoxycholic acid affects the expression of APAF1 mRNA; tauroursodeoxycholic acid affects the expression of APAF1 protein
tauroursodeoxycholic acid results in decreased expression of APAF1 mRNA
CTD PMID:15885361 NCBI chr12:98,645,141...98,735,433
Ensembl chr12:98,645,141...98,735,433
Ensembl chr12:98,645,141...98,735,433
JBrowse link
G APOA1 apolipoprotein A1 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of APOA1 mRNA CTD PMID:15885361 NCBI chr11:116,835,751...116,837,950
Ensembl chr11:116,835,751...116,837,622
Ensembl chr11:116,835,751...116,837,622
JBrowse link
G APP amyloid beta precursor protein multiple interactions EXP
ISO
tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of BCL2 protein]; tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP2 protein]; tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP6 protein]; tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of BAX protein]; tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of TRP53 protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in decreased expression of BCL2 protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in increased activity of CASP2 protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in increased activity of CASP6 protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in increased expression of BAX protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in increased expression of TRP53 protein]
tauroursodeoxycholic acid affects the reaction [APP protein modified form affects the localization of NR3C2 protein]; tauroursodeoxycholic acid inhibits the reaction [[APP protein modified form results in increased activity of CASP3 protein] which results in increased cleavage of MAPT protein]; tauroursodeoxycholic acid inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]
CTD PMID:16728529, PMID:16923170, PMID:18368144 NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,550...26,171,128
JBrowse link
G AQP8 aquaporin 8 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of AQP8 mRNA CTD PMID:15885361 NCBI chr16:25,216,917...25,228,932
Ensembl chr16:25,215,731...25,228,932
JBrowse link
G ARG1 arginase 1 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of ARG1 mRNA CTD PMID:15885361 NCBI chr 6:131,573,226...131,584,329
Ensembl chr 6:131,470,832...131,584,332
JBrowse link
G ARL1 ADP ribosylation factor like GTPase 1 increases expression ISO tauroursodeoxycholic acid results in increased expression of ARL1 mRNA CTD PMID:15885361 NCBI chr12:101,393,116...101,407,820
Ensembl chr12:101,393,116...101,407,772
JBrowse link
G AS3MT arsenite methyltransferase decreases expression ISO tauroursodeoxycholic acid results in decreased expression of AS3MT mRNA CTD PMID:15885361 NCBI chr10:102,869,470...102,901,899
Ensembl chr10:102,869,470...102,901,899
JBrowse link
G ATF4 activating transcription factor 4 decreases expression
multiple interactions
EXP
ISO
tauroursodeoxycholic acid results in decreased expression of ATF4 mRNA
tauroursodeoxycholic acid inhibits the reaction [N-palmitoylsphingosine results in increased expression of ATF4 mRNA]
tauroursodeoxycholic acid inhibits the reaction [Quercetin results in increased expression of ATF4 protein]
CTD PMID:24312631, PMID:25611565, PMID:28223344 NCBI chr22:39,514,494...39,522,686
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
JBrowse link
G ATF6 activating transcription factor 6 multiple interactions ISO
EXP
tauroursodeoxycholic acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]
tauroursodeoxycholic acid inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of ATF6 mRNA]; tauroursodeoxycholic acid inhibits the reaction [N-palmitoylsphingosine results in increased expression of ATF6 mRNA]
tauroursodeoxycholic acid inhibits the reaction [Glucosamine results in increased expression of ATF6 mRNA]; tauroursodeoxycholic acid inhibits the reaction [Quercetin results in increased activity of ATF6 protein]
CTD PMID:20165829, PMID:25611565, PMID:28223344 NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,320...161,964,070
JBrowse link
G BAD BCL2 associated agonist of cell death multiple interactions
increases phosphorylation
EXP
ISO
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [tauroursodeoxycholic acid results in increased phosphorylation of and results in decreased activity of BAD protein]; tauroursodeoxycholic acid results in increased phosphorylation of and results in decreased activity of BAD protein
tauroursodeoxycholic acid results in increased phosphorylation of and affects the localization of BAD protein; wortmannin inhibits the reaction [tauroursodeoxycholic acid results in increased phosphorylation of and affects the localization of BAD protein]
tauroursodeoxycholic acid results in increased phosphorylation of BAD protein
CTD PMID:12721362, PMID:15190125, PMID:17559149 NCBI chr11:64,269,828...64,284,704
Ensembl chr11:64,269,830...64,284,704
JBrowse link
G BAX BCL2 associated X, apoptosis regulator multiple interactions
decreases expression
increases expression
EXP
ISO
tauroursodeoxycholic acid affects the localization of and results in decreased susceptibility to BAX protein; tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of BAX protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in increased expression of BAX protein]
tauroursodeoxycholic acid results in decreased expression of BAX protein
tauroursodeoxycholic acid results in increased expression of BAX protein
tauroursodeoxycholic acid inhibits the reaction [3-nitropropionic acid affects the localization of BAX protein]; tauroursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA]
CTD PMID:11080188, PMID:12627974, PMID:12721362, PMID:15255934, PMID:16923170, PMID:17881359 NCBI chr19:48,954,825...48,961,798
Ensembl chr19:48,954,815...48,961,798
JBrowse link
G BCL2 BCL2 apoptosis regulator increases expression
multiple interactions
ISO
EXP
tauroursodeoxycholic acid results in increased expression of BCL2 mRNA; tauroursodeoxycholic acid results in increased expression of BCL2 protein
tauroursodeoxycholic acid inhibits the reaction [Gentamicins results in decreased expression of BCL2 mRNA]; tauroursodeoxycholic acid inhibits the reaction [Gentamicins results in decreased expression of BCL2 protein]
tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of BCL2 protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in decreased expression of BCL2 protein]; tauroursodeoxycholic acid inhibits the reaction [Quercetin results in decreased expression of BCL2 protein]
CTD PMID:12721362, PMID:15255934, PMID:16923170, PMID:25611565, PMID:29751043 NCBI chr18:63,123,346...63,320,280
Ensembl chr18:63,123,346...63,320,128
JBrowse link
G BCL2L1 BCL2 like 1 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of BCL2L1 mRNA CTD PMID:12721362 NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
JBrowse link
G C4B complement C4B (Chido blood group) decreases expression ISO tauroursodeoxycholic acid results in decreased expression of C4B mRNA CTD PMID:15885361 NCBI chr 6:32,014,795...32,035,418
Ensembl chr 6:32,014,795...32,035,418
JBrowse link
G CANX calnexin multiple interactions EXP tauroursodeoxycholic acid inhibits the reaction [Tunicamycin results in increased expression of CANX protein] CTD PMID:27588471 NCBI chr 5:179,678,646...179,731,641
Ensembl chr 5:179,678,628...179,731,641
JBrowse link
G CASP12 caspase 12 (gene/pseudogene) multiple interactions EXP tauroursodeoxycholic acid inhibits the reaction [Thapsigargin results in increased cleavage of CASP12 protein] CTD PMID:12198651 NCBI chr11:104,885,718...104,898,460
Ensembl chr11:104,885,718...104,898,670
JBrowse link
G CASP2 caspase 2 multiple interactions EXP tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP2 protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in increased activity of CASP2 protein] CTD PMID:16923170 NCBI chr 7:143,288,351...143,307,696
Ensembl chr 7:143,288,215...143,307,696
JBrowse link
G CASP3 caspase 3 multiple interactions
decreases activity
EXP
ISO
tauroursodeoxycholic acid inhibits the reaction [Quercetin promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein]]; tauroursodeoxycholic acid inhibits the reaction [SERPINA1 protein mutant form results in increased cleavage of and results in increased activity of CASP3 protein]; tauroursodeoxycholic acid inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP3 protein]; tauroursodeoxycholic acid inhibits the reaction [Thapsigargin results in increased activity of CASP3 protein]
tauroursodeoxycholic acid inhibits the reaction [Gentamicins results in increased expression of CASP3 mRNA]; tauroursodeoxycholic acid inhibits the reaction [Gentamicins results in increased expression of CASP3 protein]
tauroursodeoxycholic acid results in decreased activity of CASP3 protein
tauroursodeoxycholic acid inhibits the reaction [[APP protein modified form results in increased activity of CASP3 protein] which results in increased cleavage of MAPT protein]; tauroursodeoxycholic acid inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]; tauroursodeoxycholic acid inhibits the reaction [Neurotoxins results in increased activity of CASP3 protein]; tauroursodeoxycholic acid inhibits the reaction [TGFB1 protein results in increased activity of CASP3 protein]
CTD PMID:12198651, PMID:12773247, PMID:15190125, PMID:15222754, PMID:17436368, PMID:17559149, PMID:18368144, PMID:25611565, PMID:29751043 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CASP4 caspase 4 multiple interactions EXP tauroursodeoxycholic acid inhibits the reaction [SERPINA1 protein mutant form results in increased cleavage of and results in increased activity of CASP4 protein] CTD PMID:17559149 NCBI chr11:104,942,866...104,968,596
Ensembl chr11:104,942,866...104,969,366
JBrowse link
G CASP6 caspase 6 multiple interactions EXP tauroursodeoxycholic acid inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased activity of CASP6 protein]; tauroursodeoxycholic acid inhibits the reaction [APP gene mutant form results in increased activity of CASP6 protein] CTD PMID:16923170 NCBI chr 4:109,688,628...109,703,445
Ensembl chr 4:109,688,622...109,703,583
JBrowse link
G CASP7 caspase 7 multiple interactions EXP tauroursodeoxycholic acid inhibits the reaction [SERPINA1 protein mutant form results in increased activity of CASP7 protein]; tauroursodeoxycholic acid inhibits the reaction [Thapsigargin results in increased activity of CASP7 protein] CTD PMID:12198651, PMID:17559149 NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
JBrowse link
G CASP9 caspase 9 multiple interactions EXP [Chenodeoxycholic Acid co-treated with tauroursodeoxycholic acid] results in increased activity of CASP9 protein; tauroursodeoxycholic acid inhibits the reaction [Quercetin promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein]]; tauroursodeoxycholic acid inhibits the reaction [Taurodeoxycholic Acid results in increased activity of CASP9 protein] CTD PMID:12773247, PMID:14976352, PMID:25611565 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
JBrowse link
G CCN2 cellular communication network factor 2 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of CCN2 mRNA CTD PMID:15885361 NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372
JBrowse link
G CCND1 cyclin D1 multiple interactions
decreases expression
ISO tauroursodeoxycholic acid inhibits the reaction [Deoxycholic Acid results in increased expression of CCND1 protein]
tauroursodeoxycholic acid results in decreased expression of CCND1 mRNA; tauroursodeoxycholic acid results in decreased expression of CCND1 protein
CTD PMID:15885361, PMID:17431217 NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
JBrowse link
G CDH17 cadherin 17 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of CDH17 mRNA CTD PMID:15885361 NCBI chr 8:94,127,162...94,217,278
Ensembl chr 8:94,127,162...94,217,303
JBrowse link
G CDH2 cadherin 2 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of CDH2 mRNA CTD PMID:15885361 NCBI chr18:27,932,878...28,177,130
Ensembl chr18:27,932,879...28,177,946
Ensembl chr18:27,932,879...28,177,946
JBrowse link
G CEBPD CCAAT enhancer binding protein delta increases expression ISO tauroursodeoxycholic acid results in increased expression of CEBPD mRNA CTD PMID:15885361 NCBI chr 8:47,736,913...47,738,164
Ensembl chr 8:47,736,913...47,738,164
JBrowse link
G CHAC1 ChaC glutathione specific gamma-glutamylcyclotransferase 1 multiple interactions EXP tauroursodeoxycholic acid inhibits the reaction [Xylitol results in increased expression of CHAC1 protein] CTD PMID:32275922 NCBI chr15:40,942,137...40,956,518
Ensembl chr15:40,952,962...40,956,512
JBrowse link
G CITED2 Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of CITED2 mRNA CTD PMID:15885361 NCBI chr 6:139,371,807...139,374,648
Ensembl chr 6:139,371,807...139,374,648
JBrowse link
G CPS1 carbamoyl-phosphate synthase 1 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of CPS1 mRNA CTD PMID:15885361 NCBI chr 2:210,477,685...210,679,107
Ensembl chr 2:210,477,682...210,679,107
JBrowse link
G CREB1 cAMP responsive element binding protein 1 multiple interactions ISO 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [tauroursodeoxycholic acid results in increased phosphorylation of and results in increased activity of CREB1 protein]; calphostin C inhibits the reaction [tauroursodeoxycholic acid results in increased phosphorylation of and results in increased activity of CREB1 protein]; KN 62 inhibits the reaction [tauroursodeoxycholic acid results in increased phosphorylation of and results in increased activity of CREB1 protein]; tauroursodeoxycholic acid results in increased phosphorylation of and results in increased activity of CREB1 protein CTD PMID:15861431 NCBI chr 2:207,529,943...207,605,988
Ensembl chr 2:207,529,737...207,605,988
JBrowse link
G CS citrate synthase multiple interactions ISO tauroursodeoxycholic acid inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in decreased activity of CS protein]; tauroursodeoxycholic acid inhibits the reaction [N-palmitoylsphingosine results in decreased expression of CS mRNA] CTD PMID:28223344 NCBI chr12:56,271,699...56,300,330
Ensembl chr12:56,271,699...56,300,391
JBrowse link
G CSAD cysteine sulfinic acid decarboxylase decreases expression ISO tauroursodeoxycholic acid results in decreased expression of CSAD mRNA CTD PMID:15885361 NCBI chr12:53,157,663...53,181,663
Ensembl chr12:53,157,663...53,180,909
JBrowse link
G CTH cystathionine gamma-lyase decreases expression ISO tauroursodeoxycholic acid results in decreased expression of CTH mRNA CTD PMID:15885361 NCBI chr 1:70,411,268...70,441,949
Ensembl chr 1:70,411,218...70,439,851
JBrowse link
G CYP1A2 cytochrome P450 family 1 subfamily A member 2 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of CYP1A2 mRNA CTD PMID:15885361 NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
JBrowse link
G CYP27A1 cytochrome P450 family 27 subfamily A member 1 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of CYP27A1 mRNA CTD PMID:15885361 NCBI chr 2:218,781,733...218,815,293
Ensembl chr 2:218,781,749...218,815,293
JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of CYP2B3 mRNA CTD PMID:15885361 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
JBrowse link
G CYP2F1 cytochrome P450 family 2 subfamily F member 1 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of CYP2F4 mRNA CTD PMID:15885361 NCBI chr19:41,114,292...41,128,381
Ensembl chr19:41,114,432...41,128,381
JBrowse link
G CYP4F12 cytochrome P450 family 4 subfamily F member 12 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of CYP4F1 mRNA CTD PMID:15885361 NCBI chr19:15,673,023...15,698,819
Ensembl chr19:15,673,018...15,697,174
JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions ISO
EXP
tauroursodeoxycholic acid inhibits the reaction [Ethanol results in increased expression of DDIT3 protein]
tauroursodeoxycholic acid inhibits the reaction [2,4-dichlorophenol results in increased expression of DDIT3 mRNA]; tauroursodeoxycholic acid inhibits the reaction [[N-palmitoylsphingosine co-treated with Dietary Fats] results in increased expression of DDIT3 mRNA]; tauroursodeoxycholic acid inhibits the reaction [Gentamicins results in increased expression of DDIT3 mRNA]; tauroursodeoxycholic acid inhibits the reaction [Gentamicins results in increased expression of DDIT3 protein]; tauroursodeoxycholic acid inhibits the reaction [N-palmitoylsphingosine results in increased expression of DDIT3 mRNA]
tauroursodeoxycholic acid inhibits the reaction [Quercetin results in increased expression of DDIT3 protein]; tauroursodeoxycholic acid inhibits the reaction [ursolic acid results in increased expression of DDIT3 protein]
CTD PMID:23544086, PMID:24802810, PMID:25611565, PMID:27853103, PMID:28223344, PMID:29751043 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DPP4 dipeptidyl peptidase 4 decreases expression ISO tauroursodeoxycholic acid results in decreased expression of DPP4 mRNA CTD PMID:15885361 NCBI chr 2:161,992,245...162,074,215
Ensembl chr 2:161,992,245...162,074,215